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Abstract 
 
284 million people worldwide suffered from type 2 diabetes mellitus (T2DM) in 2010, 
which will, in approximately half of them, lead to the development of diabetic peripheral 
neuropathy (DPN). Although DPN is the most common complication of diabetes mellitus and 
the leading cause of non-traumatic amputations its pathophysiology is still poorly understood. 
To get more insight into the molecular mechanism underlying DPN in T2DM, I used a rodent 
model of T2DM, the db/db mice.  
In vivo electrophysiological recordings of diabetic animals indicated that in addition to 
reduced nerve conduction velocity db/db mice also present increased nerve excitability. 
Further ex vivo evaluation of the electrophysiological properties of db/db nerves clearly 
established a presence of the peripheral nerve hyperexcitability (PNH) phenotype in diabetic 
animals. Using pharmacological inhibitors we demonstrated that PNH is mostly mediated by 
the decreased activity of Kv1 channels. In agreement with these data I observed that the 
diabetic condition led to a reduced presence of the Kv1.2 subunits in juxtaparanodal regions 
of db/db peripheral nerves whereas its mRNA and protein expression levels were not 
affected. Importantly, I confirmed a loss of juxtaparanodal Kv1.2 subunits in nerve biopsies 
from type 2 diabetic patients. Together these observations indicate that the type 2 diabetic 
condition leads to potassium-channel mediated changes of nerve excitability thus identifying 
them as potential drug targets to treat some of the DPN related symptoms. 
Schwann cells ensheath and isolate peripheral axons by the production of myelin, which 
consists of lipids and proteins in a ratio of 2:1. Peripheral myelin protein 2 (= P2, Pmp2 or 
FABP8) was originally described as one of the most abundant myelin proteins in the 
peripheral nervous system. P2, which is a member of the fatty acid binding protein (FABP) 
family, is a 14.8 kDa cytosolic protein expressed on the cytoplasmic side of compact myelin 
membranes. As indicated by their name, the principal role of FABPs is thought to be the 
binding and transport of fatty acids.  
To study its role in myelinating glial cells I have recently generated a complete P2 
knockout mouse model (P2-/-). I confirmed the loss of P2 in the sciatic nerve of P2-/- mice at 
the mRNA and protein level. Electrophysiological analysis of the adult (P56) mutant mice 
revealed a mild but significant reduction in the motor nerve conduction velocity. Interestingly, 
this functional change was not accompanied by any detectable alterations in general myelin 
structure. However, I have observed significant alterations in the mRNA expression level of 
other FABPs, predominantly FABP9, in the PNS of P2-/- mice as compared to age-matched 
P2+/+ mice indicating a role of P2 in the glial myelin lipid metabolism.  
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Résumé 
 
Le diabète de type 2 touche 284 million de personnes dans le monde en 2010 et son 
évolution conduit dans la moitié des cas à une neuropathie périphérique diabétique. Bien 
que la neuropathie périphérique soit la complication la plus courante du diabète pouvant 
conduire jusqu’à l’amputation, sa physiopathologie est aujourd’hui encore mal comprise. 
Dans le but d’améliorer les connaissances moléculaires expliquant les mécanismes de la 
neuropathie liée au diabète de type 2, j’ai utilisé un modèle murin du diabète de type 2, les 
souris db/db. 
In vivo, les enregistrements éléctrophysiologiques des animaux diabétiques montrent 
qu’en plus d’une diminution de la vitesse de conduction nerveuse, les souris db/db 
présentent également une augmentation de l’excitabilité nerveuse. Des mesures menées Ex-
vivo ont montré l’existence d’un phénotype d’hyperexcitabilité sur les nerfs périphériques 
isolés d’animaux diabétiques. Grâce à l’utilisation d’inhibiteurs pharmacologiques, nous 
avons pu démontrer que l’hyperexcitabilité démontrée était due à une réduction d’activité des 
canaux Kv1. En accord avec ces données, j’ai observé qu’une situation de diabète conduisait 
à une diminution des canaux Kv1.2 aux régions juxta-paranodales des nerfs périphériques 
db/db, alors que l’expression du transcrit et de la protéine restait stable. J’ai également 
confirmé l’absence de canaux Kv1.2 aux juxta-paranoeuds de biopsies de nerfs de patients 
diabétiques. L’ensemble de ces observations montrent que les nerfs périphériques chez les 
patients atteints de diabète de type 2 est due à une diminution des canaux potassiques 
rapides juxtaparanodaux les identifiant ainsi comme des cibles thérapeutiques potentielles. 
Les cellules de Schwann enveloppent et isolent les axones périphériques d’une 
membrane spécialisée, la myéline, composée de deux fois plus de lipides que de protéines. 
La protéine P2 (Pmp2 « peripheral myelin protein 2 » ou FABP8 « fatty acid binding protein 
8 ») est l’une des protéines les plus abondantes du système nerveux périphérique. P2 
appartient à la famille de protéines FABP liant et transportant les acides gras et est une 
protéine cytosolique de 14,8 kDa exprimée du côté cytoplasmique de la myéline compacte.  
Afin d’étudier le rôle de P2 dans les cellules de Schwann myélinisantes, j’ai généré une 
souris knockout (P2-/-). Après avoir validé l’absence de transcrit et de protéine P2 dans les 
nerfs sciatiques P2-/-, des mesures électrophysiologiques ont montré une réduction modérée 
mais significative de la vitesse de conduction du nerf moteur périphérique. Il est important de 
noter que ces changements fonctionnels n’ont pas pu être associés à quelconque 
changement dans la structure de la myéline. Cependant, j’ai observé dans les nerfs 
périphériques P2-/-, une altération significative du niveau d’expression d’ARNm d’autres 
FABPs et en particulier FABP9. Ce dernier résultat démontre l’importance du rôle de la 
protéine P2 dans le métabolisme lipidique de la myéline. 
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List of abbreviations 
 
4-AP   4-aminopyridine 
ACSF   artificial cerebrospinal fluid 
APO   action potential 
CAP   compound action potential 
Co-IP   co-immunoprecipitation 
CMAP   compound muscle action potential 
CMT   Charcot-Marie-Tooth disease 
CNS   central nervous system 
CRAC   cholesterol recognition amino acid consensus 
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MNCV   motor nerve conduction velocity 
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PNS   peripheral nervous system 
qPCR   quantitative polymerase chain reaction 
RP   refractory period 
RT   room temperature 
Scap   SREBP cleavage-activating protein 
Scip   suppressed cAMP-induced POU 
SLI   Schmidt-Lanterman Incisures 
SNCV   sensory nerve conduction velocity 
STZ   Streptozotocin 
T1DM   type 1 diabetes mellitus 
T2DM   type 2 diabetes mellitus 
TBS-T   tris-buffered saline containing 0,1% Tween 
TEA   tetraethylammonium 
TTX   tetrodotoxin 
WT   wild-type
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 1 
1.  Introduction 
 
1.1 The structure of the peripheral nervous system 
The peripheral nervous system (PNS) is the bond between the central nervous system 
(CNS) (brain and spinal cord) and the body`s periphery (skin, muscles and other organs). 
The peripheral nerves serve as a “network” for the CNS to receive signals from the internal 
or external environment and, after being processed in the CNS, to send the appropriate 
responses back to the effector cell or tissue in the periphery. Therefore, the CNS and PNS 
are highly interacting with and depending on each other. However, anatomically both 
systems can be clearly separated from each other as the PNS consists of all nerves and 
ganglia outside of the brain and spinal cord. In total, a human being has 43 pairs of 
peripheral nerves, 12 cranial and 31 spinal nerve pairs, branching from the brain or spinal 
cord, respectively. 
 A peripheral nerve can be divided into three compartments. The inner most part, 
consisting of several bundles of nerve fibers, is called endoneurium. Each bundle is 
delineated by a fibroblast sheath, the perineurium, and these structures are embedded again 
in a collagenous matrix called the epineurium. Especially the epineurium contains high 
amount of adipocytes (1) (Fig. 1).  
                                                     
Figure 1 : Structure of peripheral nerves. 
Cross semithin section of a murine sciatic nerve stained with Toluidine blue. Three layers of 
connective tissue can be identified: endoneurium, perineurium and epineurium. 
 
 Besides the neuron, a second cell type is crucial for the structural and functional 
composition of peripheral nerves, which are the glial cells. Glial cells of the PNS comprise 
the Schwann cells, Satellite cells and enteric glial cells (Table 1). Other cell types that are 
present in the endoneurium, albeit less frequently, are fibroblasts, endothelial cells, 
macrophages, mast cells and dendritic cells.  
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Both neurons and glial cells have the same developmental origin, deriving from the neural 
plate which is the most dorsal part of the ectoderm. During neurulation the neural plate 
becomes infolded and separated into the neural tube and the neural crest cells. Later in 
development, the neural tube differentiates into the brain and spinal cord of the CNS and into 
the motor neurons of the PNS. However, all sensory neurons and glial cells of the PNS are 
derived from the neural crest cells which are transient, multipotent cells that migrate away 
from the dorsal part of the neural tube to the periphery. Despite the same developmental 
origin neurons and glial cells have completely different roles in the PNS. (2) 
 
1.1.1 The neuron  
 The neuron is the fundamental unit of the nervous system and is specialized in the 
transmission of electrical impulses. Functionally, neurons are commonly classified into two 
categories: sensory (= afferent) and motor (= efferent) neurons. Sensory neurons provide 
information about the external or internal environment to the CNS and their cell nuclei are 
accumulated close to the spinal cord within the dorsal root ganglia (DRGs). The CNS then 
sends the signal for the behavioural response via motor neurons to the target tissue (muscle 
or organs). The cell nuclei of motor neurons are located in the ventral horn of the spinal cord. 
Structurally (and functionally) the PNS can be divided into the somatic and autonomic PNS, 
which regulate the conscious and inconscious activities of the body respectively. Thus, 
peripheral neurons must be able to convey electrical signals along distances ranging from 
millimeters to meters. Consequently the structure of a neuron is characterized by its high 
Cell type Localization Function
Neuron cell bodies in the ventral horn 
(motor) or in DRGs (sensory) of 
the spinal cord; axons forming 
the peripheral nerve
electrical excitable cells, transmission of 
electrical signal;
Schwann cell
- nonmyelinating ensheathing small peripheral 
axons (< 1 µm)
contribute to vitality und functionality of 
unmyelinated axons; one Schwann cell 
ensheaths multiple axons forming a Remak 
bundle;
- myelinating ensheathing large peripheral 
axons (> 1 µm)
to produce myelin and isolate the axons, one 
axon can be associated with several thousand 
Schwann cells; promote nerve regeneration; 
possess phagocytic properties;
- perisynaptic at neuromuscular junctions regulating the neuronal environment; involved in 
neurotransmission;
- terminal at sensory axons regulating the neuronal environment;
Satellite cell surrounding cell bodies of 
DRGs and autonomic ganglia
controlling neuronal environment and the supply 
with nutrients and oxygen; function as diffusion 
barrier;
Enteric glia cell enveloping autonomic ganglia of 
the gut
regulating neuronal environment and activity; 
involved in intestinal immune response;
Table 1 : Major cell types of the peripheral nervous system. 
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number of cell processes (Fig. 2). First, dendrites are fine and short branched extensions, 
receiving signals in case of a motor neuron from upstream neurons and they transmit the 
information towards the cell body. The cell body contains the cell nuclei, the majority of the 
cytoplasm and all important organelles. Second, the stimulated motor neuron carries the 
information away from the cell body to the target cell or tissue via a long, singular process – 
the axon. In sensory neurons the signal transmission is reversed. During development, the 
axon is growing out from the cell body to its target directed by interactions with the 
extracellular matrix via chemoattractant or repellent molecules and by neurotrophic factors of 
the target cell. The established communication site between the axon terminal and another 
neuron or peripheral tissue is called synapse. (3) 
                        
Figure 2 : Schematic drawing of a myelinated peripheral neuron. 
The neuron is presented in blue with its major structures, including dendrites, cell body with cell nuclei, 
axon and synapse. Myelin sheaths produced by Schwann cells are labeled in green. The myelin 
sheaths of adjacent Schwann cells, referred to internodes, are seperated by the node of Ranvier. 
Each myelin sheath is crossed by cytoplasmic channels called Schmidt-Lanterman incisures. (adapted 
from (4)); 
 
 As majority of proteins of the neuron are synthesized in the cell body, they have to be 
carried out to the multiple processes of the cell. Thus, axonal transport is crucial for the 
functionality and survival of the neuron. In general, microtubuli and actin filaments serve as 
transport support. Specific adaptor proteins allow motor proteins of the kinesin family to 
recognize and bind their cargos and transport them anterogradely towards the axonal 
terminal. A retrograde transport is carried out by dynein motor proteins. Many different motor 
and adaptor proteins have already been identified for the selective transport of different 
neuronal molecules (5, 6).  
 
1.1.2 The Schwann cell and the process of myelination 
 Glial cells are not electrically excitable but are crucial for the development of the PNS as 
well as for the isolation, survival and regeneration of neurons. By numbers, the PNS has 
many more glial cells than neurons.  
The Schwann cell is the major type of peripheral glial cells and the counterpart of the 
oligodendrocyte in the CNS. The maturation of neural crest cells to mature Schwann cells, 
usually present around birth, goes through two intermediate stages (2). First, Schwann cell 
Myelin 
sheath 
Schwann 
cell nuclei 
Node of 
Ranvier Internode 
Schmidt-
Lanterman 
incisure 
Axon 
Synapse 
Dendrite 
Neuron 
nuclei 
Cell body 
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precursors can be found at embryonic stages E12/E13 in mice, followed by immature 
Schwann cells at E15/E16 in mice. Except the transition from Schwann cell precursor to 
immature Schwann cells, all stages are reversible. Furthermore, the three cell types of 
Schwann cell maturation are characterized by their close association with axons and 
dependence on axonal survival and differentiation factors.  Immature Schwann cells already 
extend processes in order to segregate axons into smaller bundles and produce the basal 
lamina. Once matured, Schwann cells exit the cell cycle and adopt either a myelinating or 
non-myelinating phenotype. Although all matured Schwann cells are theoretically able to 
synthesize myelin, Schwann cells associated with axons of a smaller size (diameter < 1 µm) 
do not produce myelin but enwrap a bundle of multiple axons only with a thin layer of 
Schwann cell membrane to separate and support them. Such bundles of unmyelinated axons 
are called Remak bundles. Schwann cells in contact with larger axons (diameter > 1 µm) 
establish a 1:1 contact with them and enwrap the underlying axon with myelin.  
Initiation and regulation of the process of myelination is relatively well characterized in the 
PNS (Fig. 3) (7). Binding of axonal Nrg1 type III to ErbB2/ErbB3 receptors on the Schwann 
cell membrane plays a critical role in the determination of the amount of myelin produced by 
Schwann cells (as myelin thickness is proportional to the axonal diameter) (8). Following this 
initial signaling events, multiple transcription factors are known to promote the initiation and 
progression of myelination (e.g. Sox10, Scip and Krox20) (9).  
                          
Figure 3 : Molecular pathways regulated by Nrg1/ErbB signaling. 
Binding of neuronal Nrg1 type III to ErbB2/3 receptors on the Schwann cell membrane regulates 
various downstream pathways as depicted, which are involved in the control of Schwann cell survival, 
migration, poliferation, differentiation and thus myelination. (taken from (7)); 
 
Myelin is a tightly packed, multilayer membrane which isolates the axonal membrane in 
order to increase the nerve conduction velocity (NCV) (Fig. 2 and 4). In the PNS, every 
myelin sheath is covered by a basal lamina, which is secreted by the Schwann cell and most 
likely essential for myelination and neuronal regeneration (10). The mechanism how the 
myelin sheath is deposited around the axon was unclear until 1989. At this time it was shown 
 5 
by Bunge et al. that the inner lip of the myelin sheath (inner mesaxon) is rotating around the 
axon and producing the new myelin layers and not the external lip (outer mesaxon) by 
rotations of the Schwann cell nuclei (11). While the medial myelin sheaths are free of 
cytoplasm, the outer and inner most layers (ab- and adaxonal membrane) still contain 
cytoplasm and the former one includes the Schwann cell nucleus.  
As the very tight compaction of the myelin layers reduces the presence of conductive 
material (cytoplasm or extracellular medium), it enhances the isolating function of it. The 
cytoplasmic leaflets of a myelinating Schwann cell membrane are fused together forming the 
dark dense line while the exoplasmic leaflets form the intraperiod line of the myelin sheath 
(12). (Fig. 4). The intracellular transport of nutrients, ions and other small molecules has to 
be assured by restricted areas of non-compacted myelin. These regions of non-compact 
myelin are called the Schmidt-Lantermann incisures (SLI) which are narrowed cytoplasmic 
channels within the internode providing access from the cell body through the whole myelin 
sheath (Fig. 2), the mesaxons to the inner- and outermost limits (Fig. 4A) and the paranodes 
to the lateral edges (Fig. 5). These regions are characterized by the absence of dark dense 
and intraperiod lines as well as by a unique subset of myelin proteins (e.g. MAG and Cx32). 
              
Figure 4 : Transversal view of peripheral nervous system myelin. 
(A) Schematic graph of the multilayer myelin sheath. The close appostion of the inner plasma 
membranes form the dark dense lines while that of the outer plasma membrane layers form the 
intraperiod lines. The cytoplasmic ridge of the outer mesaxon is shown. All peripheral nerves are 
surrounded by a basal lamina. (B) Ultrathin cross section of a murine adult  sciatic nerve. (C) Scheme 
of protein localizaion in compact myelin. (D) Myelin compaction as observed in vivo in ultrathin cross 
sections of adult murine sciatic nerve. (A) adapted from (4); (C) from (12); 
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1.1.3 Node of Ranvier 
In unmyelinated fibers ion channels are diffusely distributed along the whole nerve fiber, 
hence the electrical signal transmission is continuous and slow. Myelinated fibers are divided 
into regions of molecular, structural and functional specification which enhance the speed of 
signal conduction (13). Internodes are the consecutive myelin segments produced by a 
Schwann cell and are separated by unmyelinated gaps called nodes of Ranvier (Fig. 2 and 
5) which are flanked on each side by the paranodal and juxtaparanodel regions (Fig. 5).  
 
Figure 5 : Longitudinal view of peripheral nervous system myelin. 
(A and B) Order of the nodal domains, node of Ranvier (NOR), paranode (P) and juxtaparanode 
(JXP), in a peripheral nerve presented schematically and in vivo respectively. The molecular 
components characteristic for each domain is further described for the node of Ranvier (C), the 
paranode (D) and the juxtaparanode (E). (Scheme (A) adapted from (4) and (C-E) from (13)); 
 
 
Voltage-gated Na+-channels (Nav) are crucial for the propagation of the electrical signal 
along the axon and are highly concentrated at the node of Ranvier. Therefore, the electrical 
signal jumps from one node to the next one leading to a fast saltatory conduction velocity 
along myelinated fibers. Nav-channels are composed of one large pore-forming α-subunit, 
predominantely Nav1.6 in the PNS, and two transmembrane β-subunits. Ankyrin G anchors 
the Nav-channels to the node of Ranvier by connecting it to the cytoskeleton protein βIV 
spectrin. Other neuronal adhesion molecules, NF186 and NrCAM, interact with ankyrin G 
and might be involved in the localization of Nav-channels as well. Also present at the node, 
are voltage-gated K+-channels (Kv): Kv3.1b the function of which is still unknown and 
Kv7.2/Kv7.3 controlling the slow potassium current and nerve excitability (14, 15). Unlike in 
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the CNS, the nodes in peripheral nerves are covered by microvilli of the Schwann cell. (Fig. 
5C) 
The paranodal region is characterized by the presence of paranodal junctions, which are 
complexes of two adhesion molecules, Caspr and Contactin. These junctions connect the 
lateral margins of the myelin sheath, the paranodal loops, with the axon reflecting the closest 
neuron-glia apposition in the PNS. On the axonal site the paranodal junctions are further 
connected to the cytoskeleton protein 4.1B and on the paranodal loops with NF155. The 
paranodal junctions represent a diffusion barrier between the node and juxtaparanode (Fig. 
5D). Loss of Caspr or Contactin leads to a widening of the paranodal space and altered 
localization of juxtaparanodal ion channels (16, 17). 
The juxtaparanodal region is enriched in voltage-gated Shaker-like potassium channels 
(Kv1) that are responsible for the fast potassium conductance in axons. Kv1-channels are 
composed of four pore-forming α-subunits, either Kv1.1 or Kv1.2, and four cytoplasmic β-
subunits. The adhesion molecules Caspr2 and TAG-1 are responsible for the targeting of the 
Kv1-channels to the juxtaparanodel regions (18, 19), which are connected to 4.1B via an 
unknown PDZ domain protein (Fig. 5E).  
 
1.1.4 Myelin composition 
 Majority of cell membranes are composed of lipids and proteins mixed with a 1:1 ratio. 
The lipid bilayer of the plasma membrane defines the cell and only small, uncharged 
molecules can pass this barrier. Proteins integrated into the lipid bilayer, allows the cell to 
exchange larger, charged molecules to receive and transmit signals from the outside or to 
make contact with other cells. Indeed, the set of membrane proteins and not the lipids 
defines the functional differences between membranes of the ER, Golgi, mitochondria or 
myelin. The role of the myelin membrane is to isolate the axon from its environment. This is 
achieved by an increased lipid-to-protein ratio to 2:1 and by the presence of myelin-specific 
proteins involved in the tight compaction of the multiple layers of myelin.  
 
Lipids: 
 Phospholipids, glycolipids and cholesterol are the three major lipid classes present in 
myelin and other plasma membranes. However, the amount of cholesterol, galactolipids (= 
glycolipid), plasmalogens (= phospholipid) and saturated long-chain fatty acids (FA) are 
significantly increased in myelin membranes (20). Overall, CNS and PNS myelin have a 
similar lipid composition except that PNS myelin contains a much higher amount of 
sphingomyelin than CNS myelin (20, 21). 
 For the insulating role of myelin the optimization of the membrane fluidity, compaction and 
permeability of polar molecules, predominantly ions, is crucial. Lack of one lipid component 
can already disturb these biophysical properties of the myelin membrane as demonstarted by 
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knockout (KO) mouse models for cholesterol (22) or galactolipid synthesis (23). Thus, the 
lipid composition of myelin can be an indicator for defects in the myelin integration and/or 
nerve function. 
 
Proteins: 
 Myelin contains a large set of relatively specific proteins with significant differences 
between PNS and CNS (24-26). The three major PNS myelin proteins are MPZ, Periaxin and 
MBP (Table 2), while in the CNS these are PLP and MBP which can be found in smaller 
amounts as well in the PNS. Animal models deficient for important PNS myelin genes 
provided insight about their function and thus the myelin structure (Table 2). Overall myelin 
proteins are involved in myelin compaction, stabilization, protein transport, cell adhesion and 
signaling as well as in lipid and glucose metabolism (24).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References for the following KO mouse models: Cx32 (27), MAG (28), MBP (29, 30), MPZ  (31), 
Periaxin (32) and Pmp22 (33). 
 
 
1.2 Function of the peripheral nervous system 
 At rest, the neuronal membrane has a difference in the electrical potential between the 
outside and the inside of the cell, like every other cell. This voltage gradient is called 
membrane potential and is caused by an uneven distribution of ions along the membrane. 
The passive transport of ions is driven by the ion gradient and the selective permeability of 
the membrane with a predominance of potassium ion efflux. Consequently, the inside of the 
Table 2 : Major peripheral myelin proteins. 
Protein 
name
Abundance Function KO mouse model
Cx32 < 0,5% expressed in umcompacted myelin; 
forming gap junctions crucial for ion 
homeostasis
axonal abnormalities with 
secondary demyelination 
MAG < 0,3% expressed in uncompacted myelin 
and periaxonal space; axo-glial 
interaction and myelin integrity
late-onset degeneration of 
myelinated axons; disruption 
of paranodal loops
MBP 5 - 15% myelin compaction - to fuse the 
cytoplasmic sides of one myelin layer 
forming the dark dense line
"Shiverer-mice", severe 
tremors and demyelination in 
the CNS; increased number 
of SLI in PNS
MPZ > 50% myelin compaction - MPZ tetramers 
between two adjacent myelin layers 
forming the intraperiod line
severe hypomyelination with 
enlarged intraperiod lines; 
axonal degeneration
P2 1 - 10% still unknown; suggested role in lipid 
transport
Periaxin 5% expressed early on in adaxonal 
membrane linked to the axon, later in 
abaxonal membrane bound to basal 
lamina; myelin stabilization
neuro-muscular defects in 
regions of demyelinated 
nerve fibers
Pmp22 2 - 5% still unknown; most likely myelin 
stabilization
"Trembler-mice", hyper- 
myelination followed by 
demyelination and axonal 
defects
 9 
cell has typically -70 mV with respect to the outside. However, neurons (and muscle cells) 
possess additional voltage-gated ion channels integrated in their membrane. These channels 
allow the cells to actively modify their membrane potential and to send electrical signals from 
one cell to another. (3) 
 
1.2.1 Action potential 
 The electrical signal, triggered from the dendrites or cell body of a neuron to the tip of the 
axon, is called action potential (APO) and is produced by a consecutive exchange of ion 
currents through the plasma membrane.  
 Following the stimulation of a neuron, Nav-channels at the node of Ranvier open. The 
influx of Na+-ions causes a depolarization of the membrane potential. In case the stimulus 
depolarizes the membrane to a threshold of -55 mV an APO will be induced. The APO leads 
to the maximal depolarization of the membrane as all remaining Nav-channels open 
immediately and is thus an “all-or-none” response. Any stronger stimulation cannot further 
increase the response. Temporally delayed the juxtaparanodal Kv1-channels open leading to 
a repolarization of the APO due to an enhanced efflux of K+-ions, at about the same time the 
Nav-channels close. As the Kv-channels remain open longer than necessary to re-establish 
the initial membrane potential, it causes a transient hyperpolarization (Fig. 6A) During this 
time, called refractory period (RP), the neuronal membrane is unable to generate a new APO 
thus determining the frequency of the APO and inhibiting its reversion. Once the APO 
reached the synapse it induces neurotransmitter release to stimulate the postsynaptic neuron 
or muscle cell. However, such a stimulation can also be inhibitory causing a further 
hyperpolarization of the membrane potential and preventing the generation of an APO.(3) 
 
1.2.2 Compound action potential 
 The APO described above is the response of one single nerve fiber. However, in a 
peripheral nerve many nerve fibers are activated synchronously by a stimulus. The resulting 
response of the nerve is the sum of all individual APOs and is called compound action 
potential (CAP). If the response is recorded in the corresponding muscle it is referred to 
compound muscle action potential (CMAP).  
 Compared to the single peaked “all-or-none” response of the APO, the CAP curve has 
multiple peaks and is graded (Fig. 6B). First, as the conduction velocity is directly linked to 
the axonal diameter, the curve of the CAP can be subdivided into three components. The 
first peak corresponds to the large, myelinated and thus the fastest Aα/β-fibers, followed by 
the second peak of thinly myelinated Aδ-fibers and later the slow unmyelinated C-fibers. 
Second, at a low stimulus strength only large fibers are activated. An increase in the stimulus 
strength leads to the activation of more and more small-size axons until every fiber is 
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stimulated at the maximal stimulus. Therefore, the CAP is graded because the excitability of 
a nerve fiber is inversely correlated to its axonal diameter.  
 Alterations in the CAP area and amplitude are used in diagnostics to give information 
about the number of stimulated nerve fibers and the onset and duration of the CAP about the 
NCV (3, 34). 
        
Figure 6 : Exemplary graph of an action potential and compound action potential. 
(A) Graph showing exemplary the different stages of an APO. After being stimulated to threshold the 
membrane potential becomes depolarized due to the opening of Nav-channels. The repolarization is 
induced by a delayed opening of Kv-channels, followed by the closing of the Nav-channels. A short 
overshot of the repolarization leads to membrane hyperpolarization before reaching the membrane 
resting potential again. (B) shows a typical trace of a CAP, which is the sum of all APOs of a nerve. It 
is characterized by ist graduated shape and multiple peaks corresponding to the speed of the different 
nerve fibers respectively. 
 
1.2.3 Peripheral nerve excitability 
 The excitability of a peripheral nerve describes its ability to respond to a stimulus. As 
already described above the nerve excitability is inversely proportional to the fiber size (3). 
Alterations in the nerve excitability can lead to neurologocial disorders (35-37). Symptoms of 
peripheral nerve hyperexcitability (PNH) are muscular overaction, slow reaction, cramps and 
pain, and symptoms of peripheral nerve hypoexcitability are hypesthesia and anesthesia 
which are often characteristic for a wide range of peripheral neuropathies. However, 
alterations in nerve excitability are often associated with a normal NCV (38). 
 K+-currents are crucial for regulating the membrane potential. A reduction in the K+-current 
causes not only a less negative membrane potential but also an increase in peripheral nerve 
excitability as demonstrated in disease situation. Issac`s syndrome (= neuromyotonia) is 
characterized by PNH due to an autoimmune reaction against Kv-channels. Episodic ataxia 
type 1, Diabetes mellitus (DM), Guillain-Barré-Syndrome (GBS) or amyotrophic lateral 
sclerosis are other diseases with PNH related to defects in Kv-channels (35, 36, 39, 40). This 
was further supported by KO mouse models of Kv1-channels (41) and pharmacological block 
of the fast Shaker Kv1-channels with 4-aminopyridine (4-AP) and dendrotoxin 1 (DTX-1), two 
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known blockers of these channels, which induced PNH (42). In addition to the K+-current, the 
Na+- and Ca2+-currents can influence the nerve excitability as well (40). 
 
1.2.4 Peripheral neuropathies 
 Peripheral neuropathies are disorders of the PNS caused by diseases or damage to the 
peripheral nerve. DM is the most common cause for peripheral neuropathy and will be 
discussed in-depth in chapter 1.3. Other prominent causes for peripheral neuropathy are 
inherited (e.g. Charcot-Marie-Tooth diseases (CMT)), autoimmune-induced (e.g. GBS) and 
toxin-induced disorders (e.g. by alcohol). Due to such a large diversity it is crucial to identify 
the cause for the peripheral neuropathy in order to treat the patient accordingly.   
 CMT diseases are caused by mutations in genes encoding proteins with specific roles in 
the Schwann cell or the neuron and thus can lead to either a demyelinating, axonal or 
intermediate phenotype. Nerve conduction studies are the most common tool to distinguish 
between the different phenotypes on electrophysiological level. Reduction in amplitude 
and/or area of the motor (or sensory) response is suggestive of axonal or neuronal loss and 
reduction in NCV suggestive of demyelination or defects in the integrity of the nodal region. 
Up to date, more than 50 genes are identified to be causative for the different forms of CMT 
(43). Animal models highly contributed to the understanding of the various CMT diseases. In 
our lab, we were involved in either the characterization (33, 44) or the generation and 
characterization (45) of several mouse models for different types of CMT as listed up in 
Table 3. In addition, we developed and/or characterized Lpin1 and Scap knockout mice 
which develop peripheral neuropathy, thus demonstrating their role in the lipid metabolism of 
myelin (46, 47), however they are not (yet) linked to any human pathology (Table 3). 
 
 
 
 
  
 
 
 
 
  
GBS is triggered by an abnormal immunological response against the body’s own myelin that 
ensheats peripheral nerves (48). This might be the consequence of an infectious disease. 
Interestingly, GBS in animal models, referred to experimental allergic neuritis (EAN), can be 
induced by injections of peripheral myelin or specific protein domains of P0 (49), P2 (50) or 
Pmp22 (51).  
Table 3 : Mouse models of peripheral neuropathies used in our lab. 
Gene mutation Disease Clinical feature
Mitofusin 2 CMT2A axonal
Sh3tc2 CMT4C demyelination
GDAP1 CMT4A axonal, 
demyelinating or 
intermediate
PMP22 HNPP dysmyelination/ax
onal loss
PLEKHG5 ? demyelination or 
axonal
Lpin - demyelination
Scap - demyelination
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 1.3 Diabetes mellitus 
 DM is a group of metabolic diseases characterized by hyperglycemia resulting from 
defects in insulin secretion, insulin action or both. Its prevalence has reached epidemic rates 
with over 366 million people affected worldwide in 2011. In 2030, it is estimated that this 
number will reach ~552 million (http://www.idf.org/diabetesatlas/5e/the-global-burden).  
 A tight regulation of the glucose homeostasis is crucial for life. After a meal, the blood 
glucose level rises up immediately. In a healthy person, the glucose level is regulated by the 
secretion of the hormone insulin from the β-cells of the pancreas. Insulin induces the 
integration of the glucose transporter GLUT4 into the cell membrane of the target cells 
(muscle, adipocytes and liver) thus regulating glucose uptake (52). Glucose can be 
converted to ATP in a multiple-step reaction and thus serves as an energy source for the 
cell. In addition, liver and muscle cells are able to store glucose as glycogen via glycogenesis 
which is also triggered by insulin.(53) 
 
1.3.1 Pathophysiology 
 In diabetic patients the mechanism of glucose uptake and storage cannot be induced by 
insulin which leads to hyperglycemia. Consequently, part of the excessive blood glucose is 
released by the kidneys. The term “diabetes mellitus” is derived from the Greek word 
“siphon” for passing through and the Latin word “mel” for honey (sweet). Instead of the 
unavailable glucose, the cells of diabetic patients use fat as an alternative energy source. 
However, this can lead to acidic metabolites in the blood. 
 There are two most prominent forms of DM: type 1 and type 2 DM (T1DM and T2DM 
respectively). Although the pathologies are different, both forms cause severe secondary 
complications as heart attacks, stroke, renal failure, adult blindness and amputation of lower 
limbs. 
 
T1DM: 
 Even though T1DM is the best-known form of DM in the population, it affects only ~5-10 % 
of all diabetic patients. It is characterized by an autoimmune reaction against the insulin-
producing β-cells of the pancreas and is triggered by genetic and/or environmental factors. 
T1DM patients, usually children and adolescents, are treated by insulin supply to control the 
blood glucose levels. (53) 
 
T2DM: 
 ~90% of all diabetic patients are suffering from T2DM which correlated to 284 million 
people worlwide in 2010 (54). These patients do produce insulin, however the target tissues 
(muscle, white adipose tissue or liver) cannot respond to it, leading to so called “insulin 
resistance”. The body can compensate the insulin resistance for a while by an 
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overproduction of insulin leading to hyperinsulinaemia. However, this overproduction is not 
sufficient and already at this stage the patients will start to show a slight hyperglycemia. As a 
consequence of the insulin overproduction, the β-cells are degenerating causing β-cell 
dysfunction. At this stage, T2DM patients demonstrate severe hyperglycemia and 
hypoinsulinaemia similar to T1DM patients. T2DM appears usually in older ages, but 
nowadays it is increasingly seen in childhood and adolescence (53). The danger of the 
disease is that it is often diagnosed only very late, at the time when secondary complications 
became already irreversible (55). 
 T2DM is strongly associated with obesity but there are also other genetic and 
environmental factors influencing the development of the disease (54). An efficient treatment 
is still missing in case of T2DM. Most likely, a change to a healthier lifestyle (healthy diet, 
exercise, no alcohol and cigarettes) is the best available treatment. Moreover, hypoglycemic 
drugs and sometimes insulin supply might help regulating the blood glucose level. 
 
 Independently of the cause of the disease, chronic hyperglycemia is leading to long-term 
defects in various organs causing retinopathy, nephropathy and neuropathy in all forms of 
DM. However, the effects in T2DM are slightly milder since insulin, which has multiple 
functions in the human metabolism, is produced at least during the initial phase of this type of 
DM (53). 
 
1.3.2 Diabetic peripheral neuropathy 
 Diabetic neuropathy can impair different parts of the nervous system and is hence 
classified into four categories: peripheral, proximal, autonomic and focal. 
 Diabetic peripheral neuropathy (DPN), affecting symmetrically the distal parts of sensory 
and motor peripheral nerves in arms and legs, is the most common but also least understood 
complication of both T1DM and T2DM. The prevalence of DPN varies from 10 % in the first 
year of DM to ~50 % in patients which are diabetic for more than 25 years (56). It is 
characterized by either “positive” (paresthesia, dysesthesia, pain, cramps, fasciculations) 
and/or “negative” (hypesthesia, anesthesia, tiredness, muscle weakness) symptoms (40, 57). 
Nerve conduction studies are commonly used to diagnose DPN, showing a reduced motor 
nerve conduction velocity (MNCV) and sensory nerve conduction velocity (SNCV) in diabetic 
patients. Such functional defects in diabetic patients are often associated with loss of 
unmyelinated and/or myelinated nerve fibers, axonal swellings as well as de- and 
remyelination events leading to the formation of onion bulbs (57-60). Interestingly, while axo-
glial dysjunctions are more prominent in T1DM patients, T2DM patients show more severe 
signs of Wallerian degeneration (58). However, such morphological alterations appear only 
late and might not explain the early reduced NCV in diabetic patients. It has been 
hypothesized that metabolic changes or reduction in the nerve blood flow might be 
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responsible for the earlier DPN symptoms (55, 60). Moreover, previous clinical 
electrophysiological studies suggested that altered neuronal ion channel expression and 
function may contribute to DPN symptoms (40, 61-64). As a consequence, peripheral nerve 
hyper- or hypoexcitability, which is part of the DPN phenotype, can contribute to the positive 
or negative symptoms, respectively.  
 Despite many years of research, the development of effective therapies for DPN still 
remains challenging. To study the pathophysiology of DM and DPN in more detail animal 
models might help and might improve the evaluation of new potential treatments. 
 
1.3.3 Animal models for diabetes mellitus 
 In the field of DM research, particularly rodent models are highly contributing to the 
understanding of the genetic and environmental factors of the disease, its pathophysiology, 
the establishment of secondary complications and to the development of new therapies. 
Many different T1DM and T2DM models exist, including both spontaneous and chemically-
induced (e.g. with streptozotocin (STZ)) models (Table 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 Such a large variety makes it rather difficult to choose the correct model. Therefore, it is 
crucial to compare both the animal and human physiologies. In the last years, the db/db 
mouse strain became a well established animal model for T2DM and DPN (Fig. 7) (65, 66). 
The mutated gene in db/db mice codes for the leptin receptor in the hypothalamus of the 
brain, and binding of the receptor to the leptin hormone balances the energy intake. As a 
consequence homozygous db/db mice show typical symptoms of T2DM as polyuria (frequent 
urination), polydipsia (increased thirst) and polyphagia (increased hunger) aside from 
becoming obese within their first weeks of life. As for T2DM patients hyperinsulinaemia is 
followed by hyperglycemia. In addition, db/db mice are sterile. About DPN it is reported that 
db/db mice develop a decrease in MNCV shortly after the onset of hyperglycemia (55). 
Animal model Type of DM Mechanism
STZ rat T1DM chemically induced destroying of 
pancreatic β-cells by STZ
BB/W rat T1DM autoimmune reaction against pancreatic 
β-cells
STZ mouse T1DM chemically induced destroying of 
pancreatic β-cells by STZ
Akita mouse T1DM mutation of the insulin receptor
NOD mouse T1DM autoimmune reaction against pancreatic 
β-cells
BB/Z rat T2DM mutation in the leptin receptor
ZDF rat T2DM mutation in the leptin receptor
db/db mouse T2DM leptin receptor mutation; autosomal-
recessive
ob/ob mouse T2DM leptin mutation; autosomal-recessive
Table 4 : Established mouse models of type 1 and type 2 diabetes mellitus. 
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However, morphometric changes, including a loss of intraepidermal nerve fibers (IENF) as in 
T2DM patients (67, 68), occur only late after the onset of DM (69, 70).  
                                    
Figure 7 : Obese db/db mice and wild-type mice at 23 weeks of age. 
                                                                
1.4 Fatty acid binding proteins 
 The family of fatty acid binding proteins (FABPs) comprises low molecular mass proteins 
of ~15 kDa which bind predominantly long-chain FA and other hydrophobic molecules. These 
ligands serve as energy source and metabolic regulators of multiple enzymatic and 
transcriptional processes in the cell. Consequently, FABPs are especially present in lipid-rich 
tissues, like white adipose tissue, liver, muscles and others. FA do not only bind to FABPs 
but they also regulate the gene expression level, for instance of some FABPs by binding to 
their promoter region, or potentially of general metabolic and inflammatory factors. However, 
the biological function of FABPs is still poorly understood. The ligand binding increases 
FABPs solubility in the cytoplasm to potentially facilitate the uptake, transport and/or storage 
of lipids. Interestingly, the expression level of FABPs is thought to be most likely proportional 
to the rate of lipid metabolism within the cell. (71) 
 Both the gene and protein structures of FABPs are highly conserved. Each FABP gene 
has 4 exons separated by 3 introns. The tertiary structure of the resulting protein includes a 
10-stranded antiparallel β-barrel. The uncharged hydrophobic ligand-binding core lies inside 
the β-barrel and is surrounded by a hydrophilic surface. The N-terminal part is capped by a 
helix-loop-helix (71). 
 Up to date, 10 family members (FABP1 to 9, and 12) are described (71, 72) (Table 5), 
each characterized by its expression pattern, its ligand selectivity and affinity. Most tissues 
express several FABPs and consequently most FABPs are present in several tissues. 
FABPs expressed in the nervous system are FABP3, 5, 7 and 8. Interestingly, FABP8 is the 
only one to be expressed in the PNS and not in the CNS in most species (73). FABP4, 5, 8, 
9 and 12 are known to be clustered in the same chromosomal region (72, 74). Together with 
db/db 
WT 
0,5 cm 
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their similarity at the DNA and protein structural level, this suggests that FABPs are derived 
from one common ancestor gene. 
 The generation of KO mouse models for the majority of FABPs substantially improved our 
understanding of the role of FABPs (71). However, it also rose up new questions. Table 5 
summarizes the main outcomes of the analysis of FABP KO mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4.1 P2 
 P2 (= FABP8, Pmp2) is recognized both as a FABP and as one of the major peripheral 
myelin proteins besides MPZ and MBP (26). Its gene and protein structure is consistent with 
the other members of the FABP family as described above. In addition, previous reports (75, 
76) demonstrated that the P2 gene contains several positive and negative regulatory 
sequences in its 5` region and that two P2 mRNAs might be produced due to different 
transcription start sites (75) (Fig. 8). On the protein level, multiple regulatory regions have 
been identified as well including phosphorylation sites, cholesterol recognition amino acid 
consensus (CRAC) - motifs and potentially a myristyolation domain (77). However, except for 
Table 5 : Annotated FABP genes and phenotypes in the corresponding knockout mouse models. 
Gene Name Important facts KO mouse model
FABP1 Liver FABP; L-
FABP
FA regulates ist mRNA expression; can
bind two ligands simultaneously
healthy; variable results under high fat diet;
FABP2 Intestinal FABP; 
I-FABP
FABP2 polymorphism asscoiated with
insulin resistance in Pima Indians
elevated insulin plasma levels; males
gained weight, females not; suggested
compensation by other FABPs;
FABP3 Heart-FABP; H-
FABP
FA uptake and transport to mitochondria
in muscle cells; expression proportional to
lipid/FA exposure
FA uptake strongly impaired, resulting in
increased FFA concentrations in plasma;
switch from FA oxidation to glucose
oxidation -> less tolerance to exercises
FABP4 Adipocyte-
FABP; A-FABP, 
aP2
named aP2 due to high sequence
similarity to P2; highly regulated during
adipocyte differentiation; FA and insulin
regulate its expression; in macrophages
inducing inflammatory response and
cholesterol accumulation
in obese FABP4-/- mice, reduced
hyperinsulinaemia and insulin resistance;
loss of FABP4 compensated by
overexpression of FABP5 in adipocytes but
not macrophages; minor increase in
plasma FFA concentration
FABP5 Epidermal-
FABP; E-FABP; 
mal1
similar selectivity and affinity as FABP4 healthy, slight compensation in liver by H-
FABP; increased insulin sensitivity; minor
increase in plasma FFA concentration
FABP6 Ileal-FABP; Il-
FABP; 
gastrotropin
FABP7 Brain-FABP; B-
FABP
mainly expressed early on; strong affinity
to n-3 polyunsaturated FA; increased in
Down`s syndrom and Shizophrenia
viable without macroscopic abnormalities;
but altered emotional behaviour; attenuated
neurogenesis
FABP8 Myelin-FABP; M-
FABP; P2
see chapter 1.4.1
FABP9 Testis-FABP; T-
FABP
proposed binding of sperm membrane with
cytoskeleton; upregulated in apoptotic
testicular germ cells; 
mice are viable and fertile, sperm head
abnormalities but normal sperm function
and sperm fatty acid composition
FABP12 expressed in retina and testis but with
different pattern of expression as FABP9
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the CRAC motif which plays a role in cholesterol recognition, their relevance remains still 
elusive.   
 
 
Figure 8 : P2 gene structure. 
The P2 gene is composed of 4 exons and 3 introns which is typical for members of the FABP familiy. 
Furthermore multiple regulatory sequences in the 5‘ region of the P2 gene have been identified, 
including the TATA-box, CAAT-box, cAMP induction site and two AP-1 binding sites, as well as a 
potential second transcription start site.   
 
 As described above, P2 is mainly expressed in the PNS but can be found also in the CNS 
of some species (e.g. CNS of rabbit, bovine, human and guinea pig but not rat, mouse or 
dog) (21, 78). Overall P2 has a very unique expression pattern compared with other 
peripheral myelin proteins. First, it is present only in a proportion of Schwann cells and 
second it shows a strong expression in the Schwann cell cytoplasm (79, 80). Second, it is 
suggested to be produced on free ribosomes and to be associated with the cytoplasmic side 
of the myelin membrane and of other membranes of organelles apposed to the Schwann cell 
cytoplasm classifies P2 to a peripheral membrane protein (79). Moreover, the expression 
level of P2 varies highly between species, between different fiber tracts of the same 
organism and between separate nerve fibers within the same nerve (80).  
 KO mouse models for the different myelin genes helped us to understand the functionality 
of each of these genes and of the entire PNS (Table 2). However, such information is still 
missing for P2. As a member of the FABP family, it is suggested that P2 might be involved in 
the transport and/or storage of lipids in myelinating glial cells. High binding affinity to 
cholesterol, oleic acid, retionic acid and retinol of P2 has been observed previously (77, 81). 
Furthermore, P2 is considered to be a candidate inducing EAN, an animal model of GBS 
(50). Others have shown that P2 might rather interact with MBP or even replace it, 
highlighting its potential role in myelin compaction. 
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2.  Material and Methods 
 
2.1 Animals and human biopsies 
 
2.1.1 db/db mice 
A breeding colony to generate db/db animals was established starting with C57BL/KSJRj-
db/db mice obtained from Janvier, France (Official Strain Name: B6.BKS(D)-Leprdb/J; Stock 
Number: 000697). Generated animals were genotyped according to the previously 
established protocol by the Jackson Laboratory (http://jaxmice.jax.org/strain/000642.html). All 
animals were housed in a controlled environment with a 12 h light/12 h dark cycle with free 
access to water and standard laboratory diet. Only male animals were used for experiments. 
Only db/db mice with established hyperglycemia at the age of 6 weeks were considered as 
diabetic and used in this study. We used db/db animals exposed to diabetes for 16 weeks 
(23 weeks old). Experiments were performed in accordance with the legal requirements of 
the University of Lausanne and the Canton of Vaud.  
 
2.1.2 Human biopsies 
Biopsies have been obtained from the “Centre de Référence des Neuropathies Amyloides 
& autres Neuropathies Rares” of the Centre Hospitalier Universitaire de Bicetre in Paris 
(France). All donors gave a written consent for the biopsy. Biopsies of the peroneal nerve 
and adjacent muscle were performed under local anesthesia. The nerve specimens were 
fixed in 3,6% glutaraldehyde and embedded in paraffin for routine analysis, or were 
embedded in plastic for semithin and ultrathin sectioning analyzed by light and electron 
microscopy respectively. Paraffin sections were stained with hematoxylin-eosin and 
Masson’s trichrome. Semithin sections were stained with thionine blue.  
 
2.1.3 P2-/- mouse model 
The P2 targeted embryonic stem cells were developed by Regeneron 
(www.velocigene.com) and were used to generate the P2-/- via the service of Knockout 
Mouse Project organization (www.komp.org). While the targeted embryonic stem cells are 
publically available, we have the proprietary rights over the generated P2-/- animals. All 4 
coding exons of P2 were replaced by lacZ (in frame after the original ATG of the P2 gene) 
and neomycin cassette. To genotype mice, the combination of F, R-WT and R-lacZ primers 
were used (Fig. 19A and Table 7). PCR conditions were as described in chapter 2.3.6. As 
the annealing temperature for the wild-type (WT) allele was 56°C and for the mutant allele 
58°C two separate PCR reactions had to be prepared. WT and mutant allele amplicons were 
1039 and 484 bp long, respectively. 
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Since the neomycin cassette is flanked by loxP sites, P2-/- mice were crossed to the 
nestin-Cre deleter strain leading to the generation of P2-/-∆Neo mice. 
 
2.1.4 P2-/-/Shi-/- mice 
Shiverer mice Shi-/- (lacking MBP) were obtained from Jackson Laboratory (C3Fe.SWV-
Mbpshi/J; stock number: 001428). Animals were genotyped according to the previously 
established protocol by the Jackson Laboratory (http://jaxmice.jax.org/strain/000642.html), 
primers are listed in Table 7. First male Shi-/- mice were crossed to P2-/- females and 
secondly, the obtained double heterozygous mice P2+/-/Shi+/- were mated together in order to 
achieve double KO mice of P2 and MBP (P2-/-/Shi-/-). 
 
2.2 Physiological and electrophysiological methods 
 
2.2.1 Measurement of glycemia and plasma insulin levels 
Tail vein blood glucose was determined with a glucometer Ascencia Contour (Bayer). 
Plasma insulin levels were measured by using the Rat/Mouse Insulin Elisa Kit from Millipore 
(Cat. #EZRMI-13K) according to the manufacturer’s protocol. 
 
2.2.2 Determination of free fatty acids from blood plasma 
Blood was collected from beheaded mice and let blood clot for 30 min at room 
temperature (RT). Afterwards, the clotted blood was centrifuged for 15 min at 4°C, 
supernatant contained the plasma and was transfered into a new tube.  
To measure the concentration of free fatty acids (FFA) in the plasma the half-micro test 
from Roche (Cat. #11383175001) was used according to the manufacturer’s protocol. 
 
2.2.3 Motor and sensory nerve conduction velocity 
Animals were anesthetized with a mixture of 10 mL/g Ketanarkon 100 (1 mg/mL; Streuli) 
with 0.1% Rompun (Bayer) in phosphate buffered saline (PBS) and fixed in the prone 
position. MNCV recordings were performed as previously described (45). Briefly, both left 
and right sciatic nerves were stimulated at the sciatic notch and distally at the ankle via 
bipolar electrodes with supramaximal square-wave pulses (5 V) of 0.05 ms. The latencies of 
the CMAP were recorded by a bipolar electrode inserted between digits two and three of the 
hindpaw and measured from the stimulus artifact to the onset of the negative M-wave 
deflection. MNCV was calculated by dividing the distance between the stimulating and 
recording electrodes by the result of subtracting the distal latency from the proximal latency. 
For SNCV, the caudal nerve of the tail was stimulated distally. The sensory response was 
recorded by bipolar electrode inserted proximally at the base of the tail. Latency of the 
compound sensory action potentials was determined by measuring the stimulus artifact to 
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the onset of the S-wave deflection. SNCV was calculated by dividing the distance between 
the stimulating and recording electrode by the latency. 
 
2.2.4 Ex vivo compound action potential recording  
Recordings have been performed as previously described (44). Briefly, mice were 
anesthetized with Isofluran (Baxter) and beheaded. Sciatic nerve were dissected and placed 
in artificial cerebrospinal fluid (ACSF) composed of (in mM) : NaCl, 126 ; KCl, 3 ; NaH2PO4, 
1.25 ; CaCl2, 2 ; MgCl2, 2 ; NaHCO3, 26 ; glucose, 10 ; pH7.4 (all salts from VWR), and 
continuously bubbled with carboxygen, (95% O2/5% CO2). Nerves were allowed to 
equilibrate for 60 min before electrophysiological measurement. For recordings, nerves were 
transferred to a home made chamber perfused with ACSF. Electrical stimuli (0 to 10V) were 
applied using a suction electrode filled with ACSF at the proximal end of the nerve with an 
Omnical 2001 stimulator (World Precision Instruments). For the RP, nerves were stimulated 
with a supramaximal stimulus. CAPs were recorded in current-clamp mode at the distal end 
with a similar pipette using a Multiclamp 700B amplifier. Signals were filtered and digitized 
with a Digidata 1440A (Molecular devices). We used pClamp 10 for protocol generation, and 
data acquisition and analysis. Nerve isolation and recordings were done at room temperature 
(20-22°C). For pharmacological analysis, the isolated nerves were exposed to the drugs 
between 20 min and 1 h until the effects seem stable. TTX was purchased from Enzo Life 
Sciences, TEA and 4-AP from Sigma, DTX-1 from Alomone Labs and Flupirtine from Tocris.  
 
2.3 Histological and molecular biological methods 
 
2.3.1 Morphometric analysis 
Mice were perfused with 2,5% glutaraldehyde in PBS for 5 min. Sciatic nerves were 
dissected and postfixed by immersion in the fixative solution for 2 h at 4 °C, washed in 0.1 M 
cacodylate buffer (pH 7.3), and osmicated for 4 h in 1% OsO4 (Fluka). Nerves were rinsed in 
water, dehydrated, and embedded in Epon 812 resin (Fluka). Half-micrometer sections were 
stained with 1% toluidine blue and examined by light microscopy. Subsequent morphometric 
analyses were performed on micrographs using Image J (National Institutes of Health, 
Bethesda, MD) plug-in (g-ratio calculator) developed in collaboration with the cellular imaging 
facility of the University of Lausanne and available at http://cifweb.unil.ch. For electrone 
microcopy analysis, ultrathin sections were cut, collected on celloidin-coated single-slot grids, 
and stained with uranyl acetate and lead citrate. Preparations were observed on the electron 
microscope Philips CM 10. 
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2.3.2 Tissue fixation and embedding 
For cryostat sections the appropriate tissues were dissected and fixed with 4% 
paraformaldehyde in PBS for 10 min at RT and subsequently overnight at 4°C. After 
cryoprotection in 20% sucrose in PBS overnight at 4°C, tissues were embedded in OCT 
medium (Sakura) and longitudinal or cross sections of 8 µm were prepared. Prior to specific 
staining the slides were post-fixed in 4% paraformaldehyde for 10 min.  
Nerve biopsies were embedded directly in OCT compound (Tissue-Tek) after removal. 20 
µm thick sections were cut, dried on glass slides and fixed with Zamboni`s fixative for 15 min 
at RT. 
For teased fiber analysis, sciatic nerves were dissected and incubated for 15 min at RT in 
Zamboni’s fixative. Subsequently, nerves were washed in PBS, and individual fibers were 
separated in PBS on glass slides coated with Tespa (Sigma).  
 
2.3.3 Immunohistochemistry 
Samples were permeabilized with methanol at -20°C for 10 min. Next, specimen were 
blocked in 10% normal goat serum, 0.3% Triton X-100 in PBS for 1 h at RT and incubated 
overnight at 4°C with primary antibodies in blocking buffer (antibodies are listed in Table 8). 
The next day, the slides were washed in PBS and hybridized with the appropriate secondary 
fluorescent antibodies (Alexa Fluor 594 or 488, diluted 1:200; Invitrogen) in blocking buffer 
for 2 h at RT. Slides were washed and mounted with Vectashield mounting medium 
containing DAPI to counterstain cell nuclei (Vector Laboratories). Sections were visualized 
under a Leica SP5 AOBS confocal microscope. 
For Nile red staining on teased fibers, stock solution (Sigma) was diluted 1:1000 in 75% 
glycerol. Fibers were first stained with DAPI, washed once in PBS and subsequently 
mounted with one drop of Nile red working solution.  
 
2.3.4 Intraepidermal nerve fiber density 
Skin of hindpaws, attached to a small piece of paper, were fixed for 2 h in Zamboni’s 
fixative at RT. Followed by three washes with PBS, the hindpaws were incubated in 30% 
sucrose overnight at 4°C, embedded in OCT and stored at -80°C. Footpads were cut into   
50 µm sections, using every fourth section. Free-floating sections were blocked in 0,3 % 
Triton-X 100 in PBS overnight at 4°C. Next, the sections were incubated with the primary 
antibody against Collagen-IV overnight at 4°C, washed in PBS and subsequently incubated 
with the secondary antibody Alexa 594 anti-goat for 2 h at RT. After washes with PBS, the 
same procedure was repeated with the primary antibody for PGP9.5 and its appropriate 
secondary antibody Alexa 488 anti-rabbit, finished by washes with PBS. To mount the 
sections with Vectashield mounting media containing DAPI, the sections were transferred 
onto a slide in a drop of PBS. Four different frames of three sections per animal were 
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analyzed using a Leica SP5 AOBS confocal microscope. Z-stacks of 2 µm intervals were 
obtained and the number of nerve fibers/mm crossing the dermal-epidermal junction in the 
superimposed image was counted. 
 
2.3.5 X-Gal staining 
Sciatic nerves were fixed in 0,5% Glutaraldehyde in PBS for 2 h at RT, cryoprotected in 
30% sucrose and 2 mM MgCl2 in PBS overnight at 4°C and embedded in OCT medium. 
Sections of 8 µm thickness transferred onto a glas slide were fixed in 4°C-cold X-Gal fixative 
(4% paraformaldehyde, 0,5% glutaraldehyde, 0,1 M PBS) for 4 min. After 2x washes in PBS, 
sections were stained with 50 mg/ml X-Gal diluted 1:50 in X-Gal staining solution (5 mM 
K3Fe(CN)6, 5 mM K4Fe(CN)6◦3H2O, 2 mM MgCl2 in PBS) at 37°C. Staining reaction was 
stopped by washes in PBS at several time points ranking from 30 min to overnight. 
 
2.3.6 PCR and quantitative PCR  
Total RNA from the various tissues used here was isolated using Qiagen RNeasy lipid 
tissue kit and reverse transcripted with SuperScript III First-Strand Synthesis System for RT-
PCR (Invitrogen) following manufacturer’s instructions.  
Table 6 shows the composition of the PCR mixture and the PCR conditions were 95°C for 
5 min, followed by 35 cycles (95°C for 30 s, primer-specific annealing temperature given in 
table 7 for 30 - 45 s, and 72 °C for 2 min) and 2 min extension at 72°C. Next, loading dye 
(0,25% Orange G, 30% Glycerol, 70% H2O) was added to each PCR reaction and separated 
on a 1% Agarose gel. 
 
 
 
 
 
 
 
 
 
 
QPCR analysis was performed with the resulting cDNA, using ABI Prism 7500 Fast Real-
Time PCR system and SYBR Green (Applied Biosystems). All primers were designed to 
prevent amplification of genomic DNA. Cycling conditions were 95°C for 10 min, followed by 
40 cycles of 95°C for 15 s, and then 60°C for 1 min. Quantitation was performed using a 
standard curve established from a serial dilution of a mix of the samples. Results were 
normalized by using the reference genes Actin or Ubiquitin. All primers used are listed in 
table 7. QPCR for FABP9 was performed using Taqman probe (Applied Biosystem) and 
Component Volume (µl)
H2O 38,1
10x PCR buffer 5
50 mM MgCl2 1,5
10 mM dNTPs 1
forward primer 1
reversed primer 1
Taq DNA polymerase 
(5 units/µl) 0,4
DNAA 2
Total volume 50
Table 6 : PCR reaction mix. 
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normalized with Taqman probe against Ubiquitin. The same system and program as 
described above were used.  
 
2.3.7 Total protein extraction 
Sciatic nerve endoneurium and DRG isolated from at least three animals per genotype 
were pooled and lysed in ice-cold lysis buffer (20 mM Na2H2PO4, 250mM NaCl, 1% Triton X-
100, 0.1% SDS) supplemented with Complete protease inhibitors (Roche). After spin down 
for 15 min at 4°C, supernatant was used as protein extract. 
 
2.3.8 Western blot analysis 
Protein levels were quantified using the Bio-Rad protein assay with BSA as a standard. 
Equal amounts of protein extracts were boiled for 5 min at 95°C and were then resolved by 
8-12% SDS-PAGE and electro-transferred onto a polyvinylidene difluoride membrane 
(Amersham Biosciences). Blots were blocked in tris-buffered saline containing 0,1% Tween 
(TBS-T) supplemented with 5% milk powder for 1 h at RT and subsequently incubated 
overnight at 4°C in the same buffer supplemented with the specific primary antibody (Table 
8). After washing in TBS-T, blots were exposed to the appropriate horseradish peroxidase-
conjugated secondary antibody (Dako) in the blocking buffer for 1 h at RT. Finally, blots were 
developed using the ECL reagents (Pierce) and Kodak Scientific Imaging Films (Kodak). 
 
2.3.9 Co-immunoprecipitation 
The lysis buffer used for co-immunoprecipitation (Co-IP) was composed as followed: 25 
mM Hepes, 150 mM NaCl, 1% NP-40, 0,25% sodium deoxycholate, 10% Glycerol, 25mM 
NaF, 1mM EDTA and 1 mM Orthovanadate, supplemented with Complete protease inhibitors 
(Roche). Proteins of sciatic nerve endoneurium were extracted as explained in 2.3.7. The 
Co-IP was performed using Dynabeads coupled to protein G (Invitrogen) and the magnetic 
particle concentrator Dynal MPCTM-S from Invitrogen. Co-IP was done according to the 
manufacturer’s instructions, except the incubation temperature was 4°C instead of RT. The 
protein input reflects 10% of the total protein amount used for the Co-IP and the negative 
control was performed without antibody. 
 
2.3.10 Cellular fractionation 
Similar to total protein extraction, tissues were collected and homogenized in a pre-cooled 
lysis buffer containing 10 mM Tris-HCl pH 7,5, 100 mM NaCl, 1 mM EDTA, 1 mM Na3VO3, 
and 1% Triton supplemented with Complete protease inhibitors (Roche). For nuclear protein 
extraction, lysed tissues were spun down for 10 min at 3’000 g at 4°C and the pellet was 
resolved in lysis buffer. Supernatant was spun down again with 80’000 g for 30 min at 4°C. 
The resulting pellet contained all organelles and membrane proteins and was resolved in 
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lysis buffer supplemented with 1% CHAPS. The final supernatant presented the cytosolic 
fraction. Subsequent Western Blot analysis was performed as described in chapter 2.3.8. 
 
2.3.11 Microarray 
Total RNAs from the complete sciatic nerve of six P10-old P2+/+ and P2-/- mice were 
isolated and purified with Qiagen RNeasy lipid tissue kit. All RNA quantities were assessed 
by NanoDrop®ND-1000 spectrophotometer and the RNA quality was assessed using RNA 
6000 NanoChips with the Agilent 2100 Bioanalyzer (Agilent, Palo Alto, USA). Two RNA 
extracts per genotype were pooled together to obtain three biological replicates. For each 
pooled sample, 100 ng of total RNA were amplified using the WT sense strand Target 
Labelling kit (Affymetrix, Cat.no. 900223); 5.5 µg of the resulting sense cDNA was 
fragmented by UDG (uracil DNA glycosylase) and APE 1 (apurinic/apyrimidic endonuclease 
1) and biotin-labelled with TdT (terminal deoxynucleotidyl transferase) using the GeneChip® 
WT Terminal labelling kit (Affymetrix Cat.no. 900671, Santa Clara, USA). Affymetrix Mouse 
Gene 1.0 ST arrays (Affymetrix, Santa Clara , CA, USA) were hybridized with 2.7 µg of 
biotinylated target, at  45°C for 17 h washed and stained according to the protocol described 
in Affymetrix GeneChip® Expression Analysis Manual (Fluidics protocol FS450_0007).  
The arrays were scanned using the GeneChip® Scanner 3000 7G (Affymetrix) and raw 
data were extracted from the scanned images and analyzed with the Affymetrix Power Tools 
software package (Affymetrix). 
All statistical analysis were performed using the free high-level interpreted statistical 
language R and various Bioconductor packages (http://www.Bioconductor.org). Hybridization 
quality was assessed using the Expression Console software (Affymetrix). Normalized 
expression signals were calculated from Affymetrix CEL files using RMA normalization 
method. Differential hybridized features were identified using Bioconductor package “limma” 
that implements linear models for microarray data (82). The P values were adjusted for 
multiple testing with Benjamini and Hochberg’s method to control the false discovery rate 
(FDR) (83). Probe sets showing at least twofold change and a false discovery rate < 0.05 
were considered significant. 
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Antibody Manufacturer raised in Dilution used
Actin Sigma, A5316 mouse 1:2000
Actin Sigma, A2066 rabbit 1:200
Caspr NeuroMab, 75-001 mouse 1:100
Collagen-IV Chemicon, AB769 goat 1:40
E-Cadherin BD Transduction Labs, 610404 mouse 1:100
FABP9 R&D Systems, MAB2750 mouse 1:100 (IH), 1:500 (WB)
Histone H3 Abcam, ab 1791 rabbit 1:1000
Kv 1.1 Alomone Labs, APC-009 rabbit 1:100
Kv 1.2 NeuroMab, 75-008 mouse 1:200 (IH), 1:500 (WB)
Kvβ2 Alomone Labs, APC-117 rabbit 1:100
MBP (IH) Chemicon, MAB386 rat 1:100
MBP (WB) Santa Cruz, sc-13912 goat 1:200
Ndufs-4 Mitoscience, MS 104 mouse 1:1000
pan-Nav Sigma, S6936 rabbit 1:100
P2 (IH) Proteintech, 12717-AP rabbit 1:100
P2 (WB) Abcam, ab 36387 rabbit 1:200
PGP9.5 Ultraclone, RA95101 rabbit 1:400
α/β-Tubulin Cell Signaling, #2148 rabbit 1:1000
Gene forward primer (5` - 3`) reversed primer (5` - 3`)
Actin (58°C) GCCCTGAGGCTCTTTTCCAG TGCCACAGGATTCCATACCC
Cystatin B (55°C) TGAAGTCCCAGCTTGAATCG TAGGAGAGCTCATCGTGCCT
db/db genotyping (52°C) AGAACGGACACTCTTTGAAGTCTC CATTCAAACCATAGTTTAGGTTTGTGT
Fasn GCTGGCATTCGTGATGGAGTCGT AGGCCACCAGTGATGATGTAACTCT
FABP3 ATGGCGGACGCCTTTGTCGG TGGCAAAGCCCACACCGAGTG
FABP5 GCACCAGCAATGGGACGGGA GCATTGTTCATGACACACTCCACG
FABP7 TACGGTGGTGGGTAAGACCCGA CCCACGCCCAGAGCTTTCATG
Kv 1.1 AAGGACGGGAAACGCGAGGG ATCGATGGACGCTGGCGGG
Kv 1.2 CTGGTACCCATCTGCAAG GTGTGCTCTAGGACTGGATG
Kvβ2 AGACAGGCTCCCCCGGGATG CATGGCCCGCACGGTCTCTTC
LacZ (66°C) GGTAAACTGGCTCGGATTAGGG TTGACTGTAGCGGCTGATGTTG
MAG CGGGTTGGATTTTACCACAC CTGCCTTCAACCTGTCTGTG
MBP+/+ genotyping (58°C) AGCTCTGGTCTTTCTTGCAG CCCCGTGGTAGGAATATTACATAAC
MBP-/- genotyping (58°C) ACCGTCCTGAGACCATTGTC GTGCTTATCTAGTGTATGCCTGTG
MBP GCCTGTCCCTCAGCAGATT GCCTCCGTAGCCAAATCC
MPZ TTCACAAGTCTTCTAAGGACTCCTCG GCACTGGCGTCTGCCG
Myogenin (56°C) TTACGTCCATCGTGGACAGC TGGGCTGGGTGTTAGTCTTA
Nav 1.6 ACACTAGTGGAAGAGCTGGA ACGATCAGGTTCACAATCTC
Nestin-Cre genotyping (56°C) CAGGGTGTTATAAGCAATCCC CCTGGAAAATGCTTCTGTCCG
P2+/+ F and R-WT (56°C) TATAGAAGGGCTTAAGCATG CAGAACAAAGTCTCCACCACAC
P2-/- F and R-LacZ (58°C) TATAGAAGGGCTTAAGCATG GTCTGTCCTAGCTTCCTCACTG
P2 (58°C) AGCTCTAGGTGTGGGGTTAGCC CCATTCTCCCATCCAGCAGCGT
PMP22 TTGCTCTTCGTCTCCACCATC TCGTGTGTCCATTGCCCAC
Resistin GCTGTAAGCTGCAGGTCGCT GGAAACCACGCTCACTTCCC
Ubiquitin CAGCCACCAAGACTGACCAA CATTCACCAGTGCTATGAGGGA
Uncoupling protein 1 TCCATGTACACCAAGGAAGGACC AAGCCACAAACCCTTTGAAAAAG
Table 8 : List of antibodies. 
Table 7 : List of primers. 
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2.4 Others 
 
2.4.1 Microdissection of sciatic nerve 
Sciatic nerves from adult mice were placed in ice-cold PBS (pH 7.4). The perineurium and 
epineurium were gently dissected away from the endoneurium along the whole length of the 
nerve as previously described (84). 
 
2.4.2 Tail or toe DNA isolation 
750 µl of DNA lysis buffer composed of 50 mM Tris-HCl pH 8,0, 100 mM EDTA, 100 mM 
NaCl, 1% SDS, 0,5 mg/ml Proteinase K (Merck 1,24568) were added to the piece of tail/toe 
and incubated overnight at 56°C. After mixing 5 min, 250 µl 6 M NaCl was added, again 5 
min mixed and subsequently spin down for 5 min. Next, the liquid phase was transferred to a 
new tube, washed with 500 µl by mixing 2 min and spun down for 1 min. A second wash with 
1,5 ml ethanol was spin down for 1 min. After drying, the DNA pellet was dissoved in 100 µl 
TE by incubating it shaking at 37°C for 2 h. 
 
2.4.3 Statistics 
All data are presented as mean ± standard error of the mean. P-values have been 
calculated with the Student`s t-test or one-way ANOVA followed by Bonferroni’s Multiple 
Comparison Test. 
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3.  Results 
 
3.1 Altered distribution of juxtaparanodal Kv1-channels mediates peripheral 
nerve hyperexcitability in type 2 diabetes mellitus 
 
3.1.1 Characterization of type 2 diabetes mellitus and diabetic peripheral neuropathy 
in db/db mice 
Most people with T2DM will develop DPN leading to tingling, pain and loss of feeling. 
Even though the pathological changes are relatively well described, the molecular 
mechanisms causing DPN remain poorly understood. I used the db/db mice as a rodent 
model for T2DM to investigate the mechanism behind DPN. In order to compare the 
etiopathology of db/db mice with T2DM patients, I determined the onset of T2DM in db/db 
mice by measuring their body weight, blood glucose and plasma insulin levels in their first 
weeks of life compared to age-matched control mice (Fig. 9A-C).  
 
Figure 9 : Physiological profile of db/db and control mice during postnatal development and in 
adult mice at 23 weeks of age 
Measurements of (A) body weight, (B) blood glucose levels, (C) plasma insulin levels, (D) MNCV, (E) 
SNCV and (F) IENF illustrated the course of T2DM and DPN in db/db mice. An increase in body 
weight and blood glucose levels set the onset of T2DM at 6 weeks of age in db/db mice. Prior to this, 
db/db mice were already hyperinsulinaemic indicating insulin resistance but in adult db/db mice the 
insulin secretion was declined. DPN, demonstrated by a reduced MNCV and SNCV, was present 
immediately after the onset of T2DM. At 23 weeks of age, after 16 weeks exposed to hyperglycemia, a 
significant reduction in the number of IENF was observed in db/db mice as compared to control mice 
displaying an additional small fiber neuropathy. n= 4 from 3 to 12 weeks; n=15 at 23 weeks; n=3 for 
IENF. a from 3 to 12 weeks of age db/+ mice and at 23 weeks of age WT mice have been used as 
control mice; * p-value < 0,05 
 
 Due to an initial insulin resistance, 5 weeks old db/db mice were already 
hyperinsulinaemic but did not present any additional diabetic phenotypes corroborating 
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previous studies (66, 85). I therefore considered the onset of T2DM in db/db mice at 6 weeks 
of age, when the affected animals started to gain weight and exhibited a marked 
hyperglycemia as compared to control mice. To diagnose an implication of nerve function, I 
measured MNCV on the sciatic nerve, which is a mixed nerve, and SNCV on the tail. Already 
at this stage of the disease I observed a slight reduction of the median MNCV (39,25 m/s for 
control mice; 35,96 m/s for db/db mice) and SNCV (18,4 m/s for control mice; 13,12 m/s for 
db/db mice), indicating the presence of DPN in db/db mice. One week later the reduction in 
MNCV became significant (41,04 m/s for control mice; 32,03 m/s for db/db mice) and I 
therefore considered the onset of DPN in db/db mice at 7 weeks of age (Fig. 9D and E). 
To study the long-term consequences of T2DM on peripheral nerves, I exposed the db/db 
mice to hyperglycemia for 16 weeks (this, based on the estimated lifespan, represents ~10 
years in humans). Consequently, I performed all physiological analysis using mice that were 
23 weeks old. At this age, db/db mice were severely obese and hyperglycemic compared to 
control mice (Fig. 9A and B). The initial insulin resistance was followed by a β-cell 
dysfunction leading to a decline in the plasma insulin levels in db/db mice at 23 weeks of age 
as previously observed (66, 86) (Fig. 9C). NCV studies confirmed the significantly reduced 
MNCV and SNCV as already observed at 7 weeks of age (Fig. 9D and E). Further 
characterization of the shape of the CMAP curve from MNCV recordings showed a 
prolonged CMAP latency, duration and F-wave latency in db/db mice indicating myelin 
defects along the complete sciatic nerve. The CMAP amplitude and area did not change 
significantly between db/db and control mice excluding any axonal alterations (Table 9).  
 
 
 
 
 
 
 
However, NCV studies do not give any information about defects of small unmyelinated 
fibers, which are known to be affected in diabetic patients (67, 68). I therefore determined the 
IENF density in db/db and WT mice at 23 weeks of age. At this age, db/db mice have lost  
~50 % of their IENF as compared to WT mice (Fig. 9F) demonstrating a strong small fiber 
neuropathy as previously reported (70).  
 
3.1.2 Peripheral nerve morphology in db/db mice at 23 weeks of age 
A reduction in the speed of the NCV is suggestive of demyelination or defects in the 
integrity of the peripheral nerve myelin. However, semithin cross sections of the sciatic nerve 
of 23 weeks old db/db mice illustrated normal myelin thickness as compared to age-matched 
MNCV (m/s) Latency (ms) Duration (ms) Amplitude (mV) Area (mV/ms) F-wave latency (ms)
control 41,5 (+/- 0,82) 1,15 (+/- 0,08) 0,96 (+/- 0,13) 2,74 (+/- 0,59) 1,17 (+/- 0,28) 5,79 (+/- 0,28)
db/db 34,5 (+/- 1,8) 1,38 (+/- 0,14) 1,18 (+/- 0,19) 3,155 (+/- 1,32) 1,54 (+/- 0,44) 7,63 (+/- 0,28)
p-value 0,0035 0,0105 0,0482 0,5924 0,2765 5,1471-6
Table 9 : Properties of CMAP shape of db/db and control mice at 23 weeks of age. 
In addition to the reduced MNCV, a reduction of CMAP latency and duration were observed in db/db 
mice as compared to control mice. The F-wave latency is also significantly downregulated in db/db 
mice. However, CMAP amplitude and area were normal. n=4. 
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WT mice (Fig. 10A). Likewise, I could not observe any signs of segmental demyelination on 
db/db teased fibers stained with Nile red (Fig. 10B). Measurements of the mRNA level of two 
important peripheral myelin proteins, MPZ and PMP22, as well as g-ratio calculations (= ratio 
of axonal diameter/fiber diameter) for WT and db/db mice supported this observation (Fig. 
10C and D). 
A slight shift towards medium size axons (3,5 - 6,5 µm) was observed, leading to a slight 
decrease in the number of small axons (1 - 3,5 µm) in db/db mice at 23 weeks of age. Large 
fibers (> 6,5 µm) were not affected (Fig. 9E). In agreement with the CMAP shape analysis, 
the count of the total number of nerve fibers per sciatic nerve in WT and db/db mice revealed 
no axonal loss (insert in Fig. 9E). 
 
Figure 10 : Myelin morphology in db/db mice as compared to wild-type mice  
(A) Toluidine blue stained semithin cross sections of WT and db/db sciatic nerves of 23 weeks old 
mice showed that 16 weeks of hyperglycemia had no detectable effects on both the axonal and myelin 
structures. (B) Nile-red stained sciatic nerve teased fibers demonstrated no segmental demyelination 
or widening of the node in db/db mice as compared to WT mice at 23 weeks. (C) qPCR analysis of 
two peripheral myelin genes (MPZ and PMP22), (D) g-ratio, (E) axonal distribution and (insert in E) 
axonal count corroborated the previous results. However, both (F) Western blot analysis on DRG 
extracts and (G) co-immunostainings on sciatic nerve teased fibers revealed a strong downregulation 
of the paranodal adhesion molecule Caspr in db/db mice as compared to WT mice. (H) Depsite the 
reduction in Caspr expression, no defects on the formation of paranodal junctions (asterisks) were 
observed on longitudinal ultrathin sections. n=3 for each experiment, except semithin sections n=6; 
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As described in chapter 1.1.3, node formation and maintenance is crucial for the 
propagation of the APO. Interestingly, I observed a significant downregulation of the protein 
expression of the paranodal adhesion molecule Caspr on western blot analysis of DRG 
samples (Fig. 10F) and immunostainings on teased fibers (Fig. 10G) of db/db mice 
compared to WT mice at 23 weeks of age. As a complete loss of Caspr leads to the 
disruption of the paranodal junctions (87), I analyzed ultrathin longitudinal sections of WT 
and db/db mice for their nodal morphology. Despite the downregulation of Caspr expression, 
paranodal loops were present in db/db mice (Fig. 10H) and no defects in the nodal structure 
of db/db mice that could potentially explain a reduced NCV were observed. 
 
3.1.3 Peripheral nerve hyperexcitability in db/db mice mediated by altered Kv1-
channel activity 
While performing MNCV recordings in db/db mice at 23 weeks of age, I observed that the 
sciatic nerves of db/db mice were more sensitive to low electrical stimuli than the nerves of 
WT animals. The stimuli threshold to initiate a first response was significantly lower in db/db 
mice as compared to WT mice (p < 0,0003), indicating hyperexcitability of db/db nerves (Fig. 
11A).  
We extended our above mentioned in vivo electrophysiological characterization by ex vivo 
CAP recordings on db/db and WT sciatic nerves at 23 weeks of age. Ex vivo CAP recording 
on isolated nerves using suction electrodes has been shown to be a powerful tool to study 
nerve excitability and alterations in axonal ion channels or myelin structure (88). It allows 
recording of both Aαβ (faster and larger peak) and Aδ CAPs. We tested WT and db/db 
sciatic nerve excitability by increasing progressively the strength of the stimulation by 10 or 
100 mV steps. Typical traces of CAP of WT and db/db nerves at 300 mV or the one to get 
the maximal amplitude confirmed the presence of an increased excitability in db/db nerves 
(Fig. 11B). In the resulting normalized Aαβ CAP amplitude/stimulus strength curve we 
observed a leftward shift for db/db mice which corresponds to PNH. The threshold to 
generate an Aαβ CAP was also significantly reduced as well as the stimulus necessary to get 
50% of the maximal CAP amplitude (Fig. 11C and insert). We observed similar results with 
thinly myelinated Aδ fibers (Fig. 11D). Together these data suggest that db/db sciatic nerves 
are more excitable than WT nerves indicating the presence of PNH similar to the one 
observed in diabetic patients (89, 90). 
Alterations in the potassium currents in either disease situation or in nerves treated with 4-
AP and DTX-1, two known blockers of the fast Shaker Kv1-channels, were previously 
observed to contribute to altered axonal properties including aberrant nerve excitability (42, 
91-94). We therefore evaluated the contribution of changes in Kv1-channel activity to PNH in 
T2DM by exposing isolated sciatic nerves to 500 µM 4-AP or 100 nM DTX-1. In the nerves 
from WT mice, both treatments reproduced the increased excitability as observed in db/db 
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nerves ex vivo (Fig. 11E and F). Importantly, the 4-AP and DTX-1 treatment did not 
reproduce the same effect on db/db nerves whose excitability was only barely affected. 
These results indicate that major part of the observed PNH phenotype in db/db fibers is the 
consequence of decreased Kv1-channel activity. 
Blocking axonal Kv1-channels was previously shown to lead to an increase in the RP (95, 
96). The RP is the interval (∆t) following the generation of a first CAP where the initiation of a 
second one is inhibited. Unexpectedly, RP was not lengthened in db/db nerves (Fig. 11G). 
The time necessary to recover 50% of the maximal CAP amplitude during the second pulse 
(∆t1/2) was 2,10 (+/- 0,01 ms) in WT and 2,06 (+/- 0,11 ms) in db/db nerves. However, 4-AP 
(Fig. 11G) and DTX-1 treatments (data not shown) induced a far more significant 
enhancement of the RP in WT nerves than in db/db nerves. ∆t1/2 after 4-AP treatment was 
increased only to 2,63 (+/- 0,14 ms) in db/db compared to 6,25 (+/- 0,82 ms) in WT animals. 
These results corroborate our observation that Kv1-channel activity is decreased in 
myelinated db/db axons.  
We also tested the possibility that other ion channels might be implicated in the PNH of 
db/db mice including Nav-channels (62, 64) and slow KCNQ Kv7-channels (Kv7.2 and Kv7.3) 
(14, 97). Increased nerve excitability in human diabetic neuropathy could also potentially be 
a consequence of increased persistent nodal Nav-currents (62, 64). These currents are 
mediated by tetrodotoxin (TTX)-resistant Nav-channels. If a higher expression of these 
channels was involved in hyperexcitability, CAP in db/db should be more resistant to block by 
TTX. We measured the residual CAP amplitude after exposure to 100 nM or 1 µM TTX and 
did not observe any significant differences between WT and db/db mice (Fig. 11H) 
suggesting that TTX-resistant Nav-channels have unlikely a critical role in the noticed 
difference in excitability. Next, nodal Kv7-channels can be blocked by tetraethylammonium 
(TEA). We evaluated if TEA (10 mM), in presence of 4-AP, would induce a further increase in 
the excitability of WT nerves reaching similar values as observed in db/db nerves. However, 
the CAP amplitude/stimulus strength curve was not further shifted by co-exposure of 4-AP 
and TEA (Fig. 11I). Therefore, a potential decrease in slow Kv7-channels is as well unlikely 
implicated in the observed PNH in db/db mice. We then tested if Flupirtine, an analgesic 
which activates Kv7-channels and suppresses axonal hyperexcitability resulting from 
exposure of rat and human peripheral nerves to oxaliplatin (98), might have an improving 
effect on the db/db PNH. 10 µM flupirtine reduced significantly db/db nerve excitability 
inducing a rightward shift of the CAP amplitude/stimulus strength and a decrease of the 
threshold (p<0,05) (Fig. 11J and insert). These data confirm the functionality of Kv7-
channels in db/db mice and suggest that the Kv7-channels represent an interesting target to 
treat some of the DPN-related symptoms. 
Ultrastructural changes of the axon or the myelin sheath of single nerve fibers could also 
induce alterations in nerve excitability (99). However as shown in Fig. 10A, I excluded any 
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major morphological alterations in db/db mice at the time of PNH. These data therefore 
further support our conclusion that PNH in db/db mice is mediated predominantly by a 
decreased Kv1-channel activity and not by significant structural changes in the myelin 
sheath.  
 
 
Figure 11 : Hyperexcitability of db/db peripheral nerves due to decreased Kv1-channel function.  
(legend on next page) 
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(A) In vivo measure of the threshold stimulus to induce a first CMAP on sciatic nerves. Threshold was 
significantly decreased in db/db (n=20) as compared to WT (n=20) mice. (B-J) Data obtained 
performing ex vivo recordings of CAPs on isolated mouse sciatic nerves. (B) Typical traces of CAP of 
WT and db/db nerves at different stimulus strengths (300 mV or the one to get the maximal amplitude) 
in presence or absence of 4-AP. The amplitudes of the traces were normalized to get the same 
maximal amplitude in WT and db/db nerves. (C) Aαβ CAP amplitude of WT (n=11) and db/db (n=12) 
nerves normalized by the maximal amplitude as function of the stimulus strength. We observed a 
leftward shift of the db/db curve corresponding to PNH. Insert: a significantly reduced threshold in 
db/db nerves confirmed PNH. (D) Aδ CAP amplitude/stimulus strength curves. As for larger Aαβ 
fibers, thinly myelinated Aδ sensory fibres were more excitable in db/db (n=5) as compared to WT 
(n=7) nerves. Insert: the threshold to generate an Aδ CAP was also significantly decreased in db/db 
nerves. (E) 4-AP (500 µM), a blocker of Kv1-channels, induced hyperexcitability in WT (n=6) but not in 
db/db (n=6) nerves. Labeling of WT and db/db was the same as in (C), diamonds correspond to the 4-
AP condition. (F) DTX-1, a toxin blocking specifically Kv1-channels, had a similar effect than 4-AP on 
db/db and WT nerve excitability (n=6). (G) Effect of 4-AP on Aαβ CAP RP. The RP is represented as 
the ratio of the second CAP on the first CAP amplitude in function of the interpulse interval. 4-AP 
increased RP significantly more in WT (n=6) than in db/db (n=6) nerves. Labeling is as in (E). (H) Bar 
graph represents the residual CAP after application of 100 nM or 1µM TTX on WT and db/db nerves. 
The effect was similar for the two genotypes for both concentrations. (I) Effect of co-exposure of TEA 
(10 mM) with 4-AP (500 µM) on nerve excitability. TEA, which blocks nodal Kv7-channels, did not 
induce any further increase in excitability in WT (n=5) or in db/db (n=4) nerves. Squares correspond to 
4-AP and diamonds to 4-AP+TEA. (J) Flupirtine (10 µM), an activator of Kv7-channels, significantly 
decreased db/db nerve excitability (n=5) thus reversing PNH. Diamonds correspond to the flupirtine 
condition. Error bars indicate SEM. * p <0,05; *** p <0,001; n= number of measurements. 
 
 
3.1.4 Altered juxtaparanodal Kv1.2 localization under type 2 diabetic conditions 
As previously observed, altered channel localization may explain the decreased function 
of Kv1-channels and the consequent PNH phenotype (37, 100). Therefore, I characterized 
the Kv1-channel distribution along peripheral axons. Teased fibers of sciatic nerves from 5 
and 23 weeks old WT mice co-immunostained for Kv1.2 and pan-Nav showed typical 
accumulation of nodal Nav-subunits and specific localization of juxtaparanodal Kv1.2- 
subunits (Fig. 12A and B left panels). The same expression pattern was detected in db/db 
teased fibers at 5 weeks of age before the onset of T2DM and DPN (Fig. 12A middle 
panel). Interestingly, I observed a strong reduction of juxtaparanodal Kv1.2-subunits in db/db 
teased fibers at 23 weeks of age, whereas Nav-clusters were well preserved (Fig. 12B 
middle panel). For quantifications I evaluated the Kv1.2 signal intensity of 100 nodes, 
labeled with Nav, per genotype and per age. At 5 weeks of age only very few nodes had a 
reduced staining signal of Kv1.2 for both WT and db/db mice. This number was significantly 
increased at 23 weeks of age for db/db mice. Moreover, about one third of db/db nodes had 
no Kv1.2 signal at all  (Fig. 12A and B right panels). Interestingly, the other Kv1-channel 
subunits, Kv1.1 and Kvβ2, were not affected in their distribution in db/db mice compared to 
WT mice and were normally distributed even at juxtaparanodes with reduced or absent Kv1.2 
(Fig. 12C and D). 
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Figure 12 : Altered Kv1.2 distribution in db/db sciatic nerves at 23 weeks of age. 
(A) At 5 weeks of age, before the onset of T2DM and DPN in db/db mice, Nav-channels are 
accumulated at the node of Ranvier and Kv1.2-subunits at the juxtaparanodal regions in teased fibers 
from both WT and db/db mice. On the right, bar graphs illustrate the percentage of juxtaparanodes 
with reduced or absent Kv1.2 signal of 100 counted nodes, co-stained for Nav. At 5 weeks of age, a 
low but equal number of juxtaparanodes demonstrated an abnormal Kv1.2 clustering in WT (15 %) and 
db/db mice (13%). (B) At 23 weeks of age, WT mice showed typical expression pattern of Kv1.2 and 
Nav but in db/db teased fibers the Kv1.2 expression was strongly reduced. However, the nodal Nav-
clusters remained unaffected. As shown in the bar graph at 23 weeks of age, 80 % of juxtaparanodes 
in db/db mice had a reduced or absent Kv1.2 distribution as compared to 14 % in WT mice. (C) On the 
left, in WT mice all juxtaparanodal regions were co-localized for Kv1.1 and Kv1.2 (yellowish staining). 
On the right, while Kv1.1 was expressed in all juxtaparanodal regions in db/db teased fibers, Kv1.2 was 
lost in some of them (red colour; arrows). (D) Co-immunostainings for Kvβ2 and Kv1.2 revealed the 
same results as for Kv1.1. n=3 for all experiments, except WT at 5 weeks of age n=2; * p < 0,05. 
 
Defects in multiple molecular mechanisms can lead to the observed altered distribution of 
Kv1.2 channels and I evaluated some of them (37, 100, 101). I tested for potential changes in 
the expression of ion channel subunits in both soma-rich dorsal DRG and axon-rich sciatic 
nerve endoneurial extracts of 5 and 23 weeks old mice. In DRG, I observed no differences in 
the mRNA expression levels of Kv1.2, Kvβ2 and Nav1.6 (the major subunit of nodal Nav-
channels) at 5 and 23 weeks of age. While Kv1.1 showed a slight downregulation at 5 weeks 
of age, it is later slightly upregulated in db/db mice as compared to WT mice (Fig. 13A and 
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B). Moreover, the protein expression of the mature (glycosylated) and immature isoforms of 
Kv1.2 in DRG and in sciatic nerve endoneurium was similar between db/db and WT mice 
(Fig. 13C) indicating that Kv1.2 was normally expressed, translated and transported to the 
axon. In addition, demyelination is also known to affect juxtaparanodal Kv1-channel 
distribution (101) but db/db mice did not possess any demyelination at this age as shown in 
Fig. 10. Together, these observations indicate that most likely the juxtaparanodal Kv1.2 
channel clustering was affected under diabetic conditions. 
 
Figure 13 : Expression levels of ion channel subunits in WT and db/db mice at 5 and 23 weeks 
of age. 
(A) At 5 weeks of age, before the onset of T2DM and DPN, mRNA expression of Kv1.2, Kvβ2 and 
Nav1.6 subunits were not different in db/db versus WT DRGs whereas Kv1.1 was significantly but 
slightly lower in db/db DRGs. (B) At 23 weeks of age, after 16 weeks of hyperglycemia, Kv1.2, Kvβ2 
and Nav1.6 mRNA expression was still preserved. Interestingly, Kv1.1 expression switched being 
significantly upregulated in db/db DRGs as compared to WT DRGs. (C) Western blot analysis 
revealed an equal protein expression of immature (im.) and mature (m.) Kv1.2 isoforms in both sciatic 
nerve endoneurium and DRGs of db/db and WT mice. * p < 0,05; n=3. 
 
To assess the clinical relevance of our data, I evaluated the channel distribution in nerve 
biopsies from T2DM patients with an axonal form of DPN (Table 10). Co-immunostainings of 
Kv1.2 and pan-Nav on longitudinal sections of the peroneal nerve, a major branch of the 
mixed sciatic nerve, of control subjects revealed the typical accumulation of nodal Nav-
channels and juxtaparanodal Kv1-channels. Similar to the phenotype of db/db mice, I 
observed a significant reduction of juxtaparanodal Kv1.2 subunits in all analyzed T2DM 
patients (Fig. 14A) while nodal Nav-clusters were well preserved. 87% of the counted nodes 
had an impaired or absent Kv1.2 signal in T2DM patients as visualized in Fig. 14A. Although 
all T2DM patients presented a loss of myelinated fibers (Table 10), none of them showed 
obvious signs of segmental demyelination (Fig. 14B). 
0
0,5
1
1,5
2
Kv1.2 Kv1.1 Kvbeta2 Nav1.6
re
la
tiv
e 
m
R
N
A 
ex
pr
es
sio
n
B 
0
0,5
1
1,5
2
Kv1.2 Kv1.1 Kvbeta2 Nav1.6
re
la
tiv
e 
m
R
N
A 
ex
pr
es
s
io
n
A 5 weeks 23 weeks 
* 
* 
m. 
Kv1.2 
im. 
Kv1.2 
C 
Endoneurium DRG 
WT db/db WT db/db 
Actin α/β-Tubulin 
WT db/db
 36 
 
Figure 14 : Ion channel distribution and myelination of human nerve biopies. 
(A) Longitudinal sections of the peroneal nerve of human biopsies from T2DM and control subjects 
were immunostained for Nav and Kv1.2. As in mice, Nav-channels are accumulated at the node of 
Ranvier and Kv1.2-channels at the juxtaparanodes in control subjects. Interestingly, T2DM patients 
showed a striking loss of juxtaparanodal Kv1.2-channels as observed in db/db mice, underlying its 
clinical relevance. More than 80% of nodes in T2DM subjects expressed only Nav, in contrast to less 
than 60% in control subjects (>100 nodes per subject were counted). (B) Immunostaining for MBP and 
Nav on human biopsies did not reveal any presence of segmental demyelination in diabetic subjects 
as compared to control subjects. * p < 0,05; n=3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient Sex Age 
(y) 
Time of 
T2DM (y)
Neuropathy Symptoms Nerve morphology
08N01013 M 52 - - neurogenic muscular atrophy; 
sensory defects until knee; 
squeezed lateral cutaneous 
nerve form thigh to spinal cord;
normal
09N01460 F 63 - - chronic neurogenic muscular 
atrophy; w alking/balance 
problems since 2 years, 
progressive, sensory defetcs;
normal
10N00090 M 51 - impairment of 
L5-S1 bilateral
muscular atrophy; disease of 
vertebral discs, pain, motor and 
sensory defects
normal, rare regeneration
08N00894 M 57 3 axonal, motor-
sensory 
motor defects fast progressive, 
low er limbs as w ell sensory 
defects; amyotrophie
loss of small and medium size 
myelinated f ibers as w ell as  
unmyelinated f ibers; WD; infiltration of 
immune cells
09N01529 F 72 14 axonal, 
sensory and 
severe motor 
defects
since 4 years progressive motor-
sensory defects, hypoesthesia, 
reduced balance/vibration sense;
loss of medium and small size 
myelinated f ibers as w ell as 
unmyelinated f ibers; signs of WD and 
microangiopathy.
10N00300 M 41 n.d. axonal and 
demyelination
Paresthesia since 6 months of 
low er limbs, sensory defects at 
all 4 limbs
moderate loss of large myelinated 
f ibers; WD and oedema, inf lammatory 
processes; diabetic microangiopathy
Table 10 : Clinical profile of T2DM and control subjects. 
WD = Wallerian degeneration; 
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3.1.5 Molecular mechanism underlying the altered Kv1.2 distribution  
(preliminary data) 
As demonstrated in Fig. 13, the mRNA and protein expression level of Kv1.2 is normal 
and cannot be causative for the altered juxtaparanodal distribution of Kv1.2. Thus, I started to 
further explore the molecular mechanism behind the altered Kv1.2 distribution in T2DM. 
There is a multiple-step process from Kv1.2 protein expression until its juxtaparanodal 
membrane integration consisting of Kv1.2 maturation (glycosylation), subunit assembly, 
vesicle inclusion, axonal transport and juxtaparanodal clustering. I used endoneurial protein 
extracts of WT and db/db mice to perform Co-IP experiments against Kvβ2 (Fig. 15A). 
Preliminary data showed an increased concentration of Kvβ2 protein in the co-
immunoprecipitated samples of both WT and db/db mice compared to their corresponding 
input samples. Furthermore, I could not observe any expression of Kvβ2 in both genotypes 
co-immunoprecipitated without primary antibody (negative control) validating the set up of the 
experiment. Interestingly, it demonstrated a reduced attachment of mature Kv1.2 to Kvβ2 in 
parallel with an increased amount of immature Kv1.2 in db/db mice as compared to WT mice. 
Likewise, I observed a reduced attachment of Kvβ2 to microtubules in db/db mice. Equal 
amounts of Kv1.2 and α/β-tubulin were obtained for the input samples of both genotypes and  
normalized to actin which could not be detected in the immunoprecipitated samples.   
 
Figure 15 : Altered Kv1.2 protein interactions and subcellular localization in db/db mice at 23 
weeks of age. 
(A) Co-IP experiments of WT and db/db sciatic nerve extracts against Kvβ2 subunits showed a 
reduced binding of matured Kv1.2 but more of immature Kv1.2 to Kvβ2 in db/db mice as in WT mice. 
Moreover, Kvβ2 showed a worse binding to tubulin in db/db mice. In both WT and db/db mice no 
binding to Actin filaments was observed. (B, C) Cellular fractionation was performed to identify 
differences in subcellular Kv1.2 localization. (B) Separation of membrane (M), nuclei (N) and 
cytolasmic fractions (C) was verified by fraction specific markers including Histone H3, mitochondrial 
Ndufs-4 and Actin respectively and was compared to the total lysate (T). (C) In sciatic nerve 
endoneurium of WT mice mature Kv1.2-subunits were specifically integrated into the axonal 
membranes whereas immature Kv1.2 was only found in the cytoplasm. The amount of integrated 
mature Kv1.2-subunits was substantially lower in db/db endoneurium but immature Kv1.2 was only 
observed in the cytoplasm too. However, with this technique I observed even in the total lysate a lower 
expression of Kv1.2 in db/db mice than in WT mice. n=3 for Western blot; n=2 for Co-IP and cellular 
fractionation. m. = mature; imm. = immature; 
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Next, the inability of Kv1.2 to reach its final target at the juxtaparanodal membrane of the 
axon may lead to an altered subcellular localization within the sciatic nerve. Therefore, I 
performed cellular fractionation to characterize Kv1.2 subcellular distribution. Efficient 
separation of proteins found in nuclei, membrane or cytosol was confirmed with specific 
markers for each fraction by immunoblot analyses on test samples (Fig. 15B). While in the 
total protein extract of WT mice both the immature and mature forms of Kv1.2 were present, 
the two isoforms were separated into two distinguished subcellular fractions (Fig. 15C). In 
the WT situation all matured Kv1.2 were integrated into the axonal membrane in the lysate of 
sciatic nerve endoneurium whereas immatured Kv1.2 was exclusively found in the cytosol 
fraction. I observed the same subcellular separation in db/db animals, however the amount of 
integrated mature Kv1.2 was much lower in db/db mice as in WT mice. Unexpectedly, I even 
could not detect any mature Kv1.2 in the total extract of the cellular fractionation experiment 
of db/db animals. 
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3.2 Generation of a knockout mouse model to study the role of peripheral 
myelin protein P2 
 
3.2.1 Selective P2 expression in a subset of Schwann cells in wild-type mice 
 Previous publications indicated that P2 may play a role in PNS myelination (79, 80). 
However, the functional role of P2 remains still unknown.  
 To date, P2 (= FABP8) is the only family member of FABPs known to be expressed in the 
PNS. I made use of the microarray data generated in our laboratory (102) to evaluate the 
expression levels of all FABP family members (see table 5) in the PNS, either in DRGs (= 
neuronal expression) or in sciatic nerve endoneurium (= glial expression). Interestingly, I 
observed an expression for three FABPs: FABP3, FABP5 and P2 (Fig. 16A to C). While 
both FABP3 and FABP5 were predominantly expressed by DRG neurons, P2 was the only 
FABP specifically expressed by Schwann cell in sciatic nerve endoneurium. Furthermore, the 
neuronal FABPs showed a more constant expression from birth until 28 months of age 
whereas P2 demonstrated a very dynamic expression profile. At birth it starts to be 
expressed, reaching its maximal expression after 2 weeks of age before being decreased 
again. Genes involved in the process of PNS maturation and which are as well expressed 
specifically by Schwann cells, e.g. MPZ and MBP, revealed a similar mRNA expression 
pattern as P2 during PNS myelination (Fig. 16D) thus highlighting its role as a PNS myelin 
gene. But unlike the other myelin genes whose expression were absent in older ages, P2 
remained expressed albeit at a lower expression level in mature myelinated Schwann cells. 
In addition, Scip, a transcription factor involved in the Schwann cell differentiation (103), is 
expressed prior to all myelin genes and downregulated with the beginning of myelination. 
Furthermore, I have also observed a similar profile of P2 expression at the protein level, 
where I detected its maximal amount in sciatic nerve samples of P10 old mice (Fig. 16E). 
qPCR analysis of various neuronal and non-neuronal tissues from adult WT mice confirmed 
the Schwann cell-specific expression of P2 (Fig. 16F). 
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Figure 16 : Expression profiles of FABPs present in the peripheral nervous system. 
(A) FABP3 and (B) FABP5 revealed a strong neuronal mRNA expression profile in mouse DRGs from 
birth until 28 months of age with only a minor expression in sciatic nerve endoneurium. (C) P2 (= 
FABP8) showed a highly specific and dynamic mRNA expression in Schwann cells enriched in sciatic 
nerve endoneurium. (D) Similar to MBP and MPZ, P2 is predominantly expressed during the first two 
weeks after birth. However, P2 is still expressed during aging (P56 until 28 of months). In contrast, 
Scip is expressed prior to all myelin genes. (E) Western Blot analysis confirmed the dynamic 
expression profile of P2 during postnatal development. (F) qPCR analysis demonstrated tissue-
specific P2 mRNA expression only in sciatic nerve endoneurium as compared to other neuronal and 
non-neuronal tissues of adult mice (P56) as indicated.  
 
 In order to localize P2 expression in the sciatic nerve, I performed co-immunostainings of 
P2 and MBP on cross sections of P10- old mice (Fig. 17A and B). Both MBP and P2 were 
detected in the myelin sheaths of Schwann cells. Interestingly, while MBP labeled all myelin 
sheaths, only some of them were P2-positive which confirmed previous observations (80). 
Furthermore, unlike MBP, P2 was also detected in the Schwann cell cytoplasm (Fig. 17B). 
The observation that P2 is expressed in only some of the myelin sheaths rises up the 
question of what distinguishes P2-postive and P2-negative Schwann cells. As suggested 
earlier (80), it could be the function or the size of the nerve fiber. First, co-immunostainings 
on dorsal and ventral roots containing only sensory or motor nerve fibers respectively, 
revealed P2 expression in myelin sheaths of both roots (Fig. 17C and D).  
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Figure 17 : P2 protein localization in wild-type sciatic nerve and roots. 
(A) In cross sections of WT sciatic nerves at P10 all myelin sheaths were immunolabeled with MBP, 
however only a subset of them expressed P2. (B) Higher magnification confirmed a strong 
cytoplasmic expression of P2 in Schwann cells (asterisks). Co-immunostainings of MBP and P2 on (C) 
ventral and (D) dorsal roots showed P2 expression of both Schwann cells associated with motor or 
sensory fibers respectively. (E) Adult sciatic nerve teased fibers confirmed the partial expression of P2 
by Schwann cells and moreover revealed changes in P2 expression of adjacent Schwann cells along 
the same nerve fiber (arrow). Teased fibers stained for P2 and (F) Caspr or (G) E-Cadherin, which are 
markers of non-compact myelin at paranodes and SLI respectively, showed a specific localization of 
P2 in compact myelin. n=3 for sciatic nerves; n=2 for roots. 
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 This observation excludes the functionality of the fiber as determinant and is in agreement 
with an earlier study (80). Second, on immunostainings of sciatic nerve cross sections, P2 
seemed to be expressed preferentially by large fibers (Fig. 17B). Co-immunostainings of 
teased fibers of adult sciatic nerves for MBP and P2 confirmed the selective Schwann cells 
expression of P2 (Fig. 17E). However, it also demonstrated that neuronal size cannot be the 
only factor determining P2 expression as adjacent myelin segments along the same nerve 
fiber could switch from being P2-positive to P2-negative.  
 Next, I asked if P2 is specific for compact or non-compact myelin. To answer this 
question, I performed co-immunostainings on adult teased sciatic nerve fibers with P2 and 
Caspr or P2 and E-Cadherin. Both are markers for regions of non-compact myelin, the 
paranodes and SLI respectively. As shown in Fig. 17F and G, P2 did not co-localize with 
these markers of non-compact myelin. Therefore, P2 is specifically expressed in compact 
myelin. 
 
3.2.2 P2 expression profile in mouse models of peripheral neuropathies 
 P2 expression profile alone makes it difficult to understand its role in PNS myelination. As 
analysis under disease-like situations helps figuring out the role(s) of a gene. Therefore, I 
compared the P2 mRNA expression in various mouse models of peripheral neuropathy, 
namely Lpin1 (Lpin1-/-), Pmp22 (Pmp22-/-) and Scap (Scap-/-) KO mouse models at P56 (102) 
(Fig. 18A). In all three situations a reduction in myelin has been observed, correlated with a 
significant downregulation of the major PNS myelin genes MPZ, MBP and Pmp22. In 
contrast, P2 was only downregulated to a minor extent in Lpin1-/- and Pmp22-/- mice, whereas 
in Scap-/- mice P2 was even slightly upregulated at P56. Uncompacted genes, like MAG, are 
however upregulated in both Scap-/- and Pmp22-/- mice and did not correlate with the 
expression pattern of P2. Again, this observation reflects a unique situation for P2.  
 Performing immunostainings on sciatic nerve cross sections of adult Lpin1+/+ and Lpin1-/- 
mice at P56 (Fig. 18B) clearly demonstrated the severe demyelination effect in Lpin1-/- mice. 
However, P2 was still well expressed in many myelin sheaths of mutant mice. The reduced 
P2 mRNA expression in Lpin1-/- mice as shown in Fig. 18A might be caused by the overall 
reduction of the number of myelinated SCs (47). While in Lpin1+/+ mice predominantly myelin 
sheaths of large fibers were P2-positive, in Lpin1-/- mice there were apparently myelin 
sheaths of both P2-positive large and small fibers. Moreover, the cytoplasmic expression in 
Lpin1-/- mice was more prominent as in Lpin1+/+ mice, potentially correlating with the higher 
amount of immature Schwann cells in the Lpin1-/- mice. Interestingly, few myelin sheaths in 
the Lpin1-/- mice expressed only P2 but not MBP which was never observed in WT mice (at 
P10 and P56). 
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Figure 18 : P2 expression in mouse models of peripheral neuropathy. 
(A) Comparison of changes of P2 mRNA expression in mouse models of demyelination (Lpin1-/-), 
dysmyelination (Pmp22-/-) and hypomyelination (Scap-/-) revealed no congruence with any other myelin 
gene. P2 being the only marker downregulated in Lpin1-/- and Pmp22-/- mouse models and slightly 
upregulated in Scap-/- mice. (B) Co-immunostainings of P2, MBP and the merge of both on sciatic 
nerve cross sections of P56-old Lpin1+/+ and Lpin1-/- mice. It clearly showed the demyelinating 
phenotype in Lpin1-/- mice but a similar P2 expression pattern for both genotypes. However, few 
myelin sheaths in Lpin1-/- mice expressed only P2 and not MBP which was never seen in Lpin1+/+ mice 
(arrows). The cytoplasmic expression of P2 in Lpin1-/- was more obvious than in Lpin1+/+ mice 
(asterisks). n=3. 
 
3.2.3 Characterization of P2-/- mouse strain with preserved myelination 
 In order to study the role of P2 in vivo, I have generated a P2 KO mouse model  (P2-/-) 
with a complete loss of P2. The P2 targeted embryonic stem cells were developed by 
Regeneron (www.velocigen.com) and were used to generate the P2+/- mice via the service of 
Knockout Mouse Project organization (www.komp.org). In a mutated allele all 4 coding exons 
of P2 were replaced by a LacZ-neomycin cassette in frame after the original ATG start codon 
of the P2 gene (Fig. 19A). Since the inserted neomycin gene was flanked by loxP sites, 
homozygous P2-/- mice were crossed with the deleter strain nestin-Cre. Elimination of the 
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neomycin-gene lead to the generation of P2+/-∆neo mice. However, all experiments described 
here were performed with P2-/- mice. 
 The successful disruption of the P2 gene was confirmed on both mRNA and protein 
levels. As shown in Fig. 19B for PCR and in Fig. 19C for Western blot analysis, the level of 
P2 expression in sciatic nerve endoneurium was substantially decreased in P2+/- mice and 
absent in P2-/- mice at P56. Co-immunostainings of P2 and MBP on sciatic nerve cross 
sections of P10-old P2-/- and P2+/+ mice confirmed the loss of P2 expression in all Schwann 
cells (Fig. 19D). Furthermore, I verified by PCR the LacZ expression in P2+/- and P2-/- but not 
in P2+/+ mice (Fig. 19B). The functionality of the LacZ gene was assayed by the enzymatic 
reaction of X-Gal. Interestingly, in samples of P2+/- mice the majority of myelin sheaths was 
stained in blue (Fig. 19E), more than P2-positive immunostained myelin sheaths in P2+/+ 
mice (Fig. 19D). 
 
Figure 19 : Generation of P2-/- mice. 
(A) Strategy for the generation of P2-/- mice. The complete P2 gene was replaced by the LacZ-
neomycin cassette. As the neomycin-gene was flanked by FloxP-sites it was removed by crossing P2-
/-
 mice to the deleter strain nestin-Cre. (B) QPCR analysis for P2 and LacZ, (C) Western Blots against 
P2, (D) co-immunostaining against P2 and MBP and (E) enzymatic reactions for β-Gal confirmed a 
reduced P2 expression in P2+/- mice and a complete loss of P2 in P2-/- mice together with the 
successful integration of the LacZ gene. 
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 P2-/- mice developed normally, were fertile and produced offspring in the normal 
Mendelian ratio (Fig. 20A). They had normal body weight and blood glucose levels 
compared to age-matched control mice at P10 and P56 (Fig. 20B and C). Interestingly, the 
plasma insulin level tended to be lower in young (P10-old) P2-/- mice (not significant) 
whereas the older mice (P56) had significantly increased plasma insulin levels as compared 
to age-matched P2+/+ mice indicative of insulin resistance (Fig. 20D). The plasma levels of 
FFA were not altered in both P10- and P56-old P2-/- mice as compared to P2+/+ mice (Fig. 
20E). To check for presence of any defects in the PNS, I performed MNCV measurements 
on the sciatic nerves of P2+/+ and P2-/- mice at P28 (P10 too young to be measured) and P56 
(Fig. 20F). At both ages, I observed a slight reduction in the MNCV which became significant 
at P56 suggestive for a demyelinating phenotype of peripheral nerves. To further 
characterize this electrophysiological differences between P2-/- and P2+/+ mice at P56 I 
compared the properties of the shape of the CMAP (Table 11). While CMAP latency and 
duration were normal in P2-/- mice, CMAP amplitude and area were significantly increased as 
compared to P2+/+ mice at P56. 
 
Figure 20 : Physiological characterization of P10- and P56-old P2-/- mice as compared to P2+/+ 
mice. 
(A) Phenotypically adult P2-/- mice were healthy with no alterations in (B) body weight and (C) blood 
glucose levels as compared to age-machted P2+/+ mice. (D) Interestingly, the plasma insulin level was 
significantly increased in P56-old P2-/- mice versus P2+/+ mice while (E) the level of plasma FFA 
showed no alterations. (F) MNCV was significantly lower in P2-/- mice as compared to P2+/+ mice at 
P56. n=5 at P10; n=3 at P28; n=10 at P56. 
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 To evaluate potential morphological abnormalities in the sciatic nerve of P2-/- versus P2+/+ 
mice semithin cross sections of the sciatic nerve at P10 and P56 were performed (Fig. 21A 
and C). Surprisingly, no gross alterations during the development (P10) and in the 
maintenance (P56) of the PNS could be observed. Additional quantitative measurements on 
the semithin cross sections including g-ratio calculations (Fig. 21B and D), axonal 
distribution (Fig. 21E) and axonal counting (Fig. 21F) excluded any major demyelinating or 
neuronal phenotypes in P2-/- mice as compared to age-matched P2+/+ mice.  
 Crucial for the generation and transmission of an APO along myelinated nerve fibers is the 
exchange of Na+- and K+-ions at the nodal region. Therefore, I analysed the presence and 
localization of the corresponding voltage-gated Nav- and Kv1-channels of adult sciatic nerve 
fibers of P2+/+ and P2-/- mice at P56. Immunostainings on teased fibers revealed the typical 
accumulation of Nav-channels at the node of Ranvier and Kv1-channels at the juxtaparanode 
in both P2+/+ and P2-/- mice (Fig. 21G). 
MNCV (m/s) Latency (ms) Duration (ms) Amplitude (mV) Area (mV/ms)
P2+/+ 39 (+/- 1,0) 1,13 (+/- 0,09) 0,8 (+/- 0,17) 3,59 (+/- 0,62) 1,34 (+/- 0,14)
P2-/- 33,78 (+/- 3,29) 1,04 (+/- 0,07) 0,83 (+/- 0,1) 7,04 (+/- 1,09) 2,78 (+/- 0,26)
p-value 0,0055 0,2367 0,7866 0,0065 0,0044
Table 11 : Properties of the CMAP curve of P2-/- and P2+/+ mice at P56. 
In addition to a significant reduction of the MNCV, the CMAP amplitude as well as the CMAP 
area was significantly increased in P2-/- mice as compared to P2+/+ mice at P56. CMAP latency 
and duration was not different. n=3. 
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Figure 21 : Preserved myelination of P2-/- sciatic nerves at P10 and P56. 
Any early (P10) or late (P56) defects in PNS myelination has been observed in P2-/- mice as compared 
to age-matched P2+/+ mice. (A and C) Semithin cross sections stained with Toluidin Blue, (B and D) g-
ratio calculations, (E) measurements of the axonal distribution and (F) total nerve fiber counts of 
sciatic nerves revealed no changes in peripheral nerves caused by the loss of P2 expression. (G) In 
sciatic nerve teased fibers of P56-old P2+/+ mice Nav-channels are accumulated at the node of Ranvier 
while Kv1-channels, labeled against Kv1.2, are clustered at the juxtaparanodes. The same distribution 
of both ion channels was observed in P56-old P2-/- mice. n=3; 
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3.2.4 Gene expression profiling of P2-/- mice identified differentially gene expression 
of other FABP family members 
 To comprehensively check for any alterations in gene expression in P2-/- mice, I performed 
microarray analysis of the sciatic nerve of P10-old P2+/+ versus P2-/- mice. I chose P10-old 
mice as this time-point reflects the main peak of the P2 expression and in order to identify 
early, and therefore predominantly primary, effects in the process of myelination.  
 A strong downregulation of P2 gene expression in P2-/- mice confirmed the loss of P2 in 
our mouse model (Fig. 22). Interestingly, the P2 deficiency had no influence on the gene 
expression of any other myelin or lipid gene crucial for the process of myelination. However, I 
observed alterations in the gene expression of other FABP family members. In particular, 
FABP9 was significantly upregulated and FABP5 significantly downregulated. Contrary to 
FABP9, FABP5 was already strongly expressed in P2+/+ mice. In addition, a minor (not 
significant) downregulation of multiple adipocyte-related genes (Resistin, Adiponectin, Ucp1 
and Car3) was revealed. 
 
Figure 22 : Transcriptional changes in P2-/- sciatic nerve endoneurium at P10. 
Microarray data of P2-/- versus P2+/+ sciatic nerve endoneurium at P10, confirmed a strong 
downregulation of P2 in P2-/- mice by which no other major myelin (MBP, MPZ, MAG) or lipid genes 
(Fasn, Srebp1, Srebp2) was influenced. The only genes being significantly differentially expressed are 
FABP5 and FABP9. Adipocyte-related genes (Resistin, Adiponectin, Ucp1, Car3) showed a (not 
significant) downregulation of more than twofold. * adjusted p-value < 0,05. Red lines inidcate 
foldchange of 1 (= no change in expression in P2-/- mice versus P2+/+ mice). 
 
 Next, I performed qPCR analysis of P56-old P2+/+ and P2-/- mice to corroborate the 
microarray results (Fig. 23). First, at this age it was possible to separate the endoneurium 
from the epi- and perineurium, which contain a high amount of adipocytes. Second, FABP5 
and FABP9 were highly expressed in white adipocyte tissue and testis/ovaries respectively 
(see table 5). Therefore these tissues were used as control tissues. As expected, P2 was 
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specifically expressed in sciatic nerve endoneurium of P2+/+ mice but in none of the tissues in 
P2-/- mice (Fig. 23A). I confirmed the strong upregulation of FABP9 and mild downregulation 
of FABP5 in P2-/- sciatic nerve endoneurium. However, both changes in gene expression 
were also present in the other tissues tested and thus were not sciatic nerve endoneurium 
specific (Fig. 23B, C). Resistin was highly expressed in lipid-rich tissues as white adipocyte 
tissue and epi- and perineurium but not in sciatic nerve endoneurium in both P2+/+ and P2-/- 
mice. While I observed no differential expression of Resistin in white adipocyte tissue, it was 
downregulated in epi- and perineurium of P2-/- mice as compared to P2+/+ mice at P56 (Fig. 
23D). Thus, the differential gene expression of adipocyte-related genes is most likely derived 
from the adipocytes of the epi- and perineurium and not from Schwann cells in the 
endoneurium. Normal expression of the major myelin and lipid genes was confirmed by using 
an independent sample of sciatic nerve endoneurium of P10-old P2-/- and P2+/+ mice (Fig. 
23E). Moreover, I observed no alterations even later at P56 using P2-/- and P2+/+ sciatic nerve 
endoneurium. 
                     
Figure 23 : Comparison of microarray results with qPCR measurements of selected genes. 
(A) P2 was specifically expressed in P2+/+ sciatic nerve endoneurium and in none of the tissues in P2-/- 
mice at P56. Slight expression in epi-/perineurium might be due to some residual Schwann cells after 
dissection. (B) FABP9 was also significantly higher expressed in P56-old P2-/- as compared to P2+/+ 
sciatic nerve endoneurium. FABP9 was upregulated in epi-/perineurium and ovaries of P2-/- mice too. 
(C) Likewise, FABP5 was donwregulated in sciatic nerve endoneurium as well as for other tissues 
tested in P56-old P2-/- mice as compared to age-matched P2+/+ mice. (D) While Resistin was not 
expressed in sciatic nerve endoneurium of both genotypes, it showed a specifc downregulation only in 
P2-/- epi-/perineurium. (E) No alterations in mRNA expression for any myelin or lipid gene was 
observed in P10-old and P56-old P2-/- mice as compared to age-matched P2+/+ mice. n=2 with pooled 
RNA of 3 mice per genotype each time. Epi, Peri = epineurium, perineurium; WAT = white adipocyte 
tissue. All data normalized to P2+/+ endoneurium = 1; * p-value < 0,05. 
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 To evaluate the FABP9 protein expression in P2-/- mice, I performed western blot analysis 
on P2-/- and P2+/+ sciatic nerves and testis, used as control tissue (Fig. 24A). First, I obtained 
a strong FABP9 expression in both P2-/- and P2+/+ testis at P56. Taking in consideration the 
normalized protein amounts of Actin, FABP9 might be slightly increased in P2-/- testis as 
compared to P2+/+ testis. However, I was unable to detect any FABP9 expression in the 
sciatic nerve of P10-old P2-/- as well as in P2+/+ mice. Furthermore, I obtained similar results 
by performing immunostainings on testis at P56 and on sciatic nerves at P10. Cross sections 
of the seminiferous tubules of P2-/- and P2+/+ testis showed a specific localization of FABP9 in 
late elongating spermatids in both genotypes. Interestingly, the intensity of staining was 
much more intense for P2-/- testis than for P2+/+ testis (Fig. 24B). As FABP9 is not expressed 
in P2+/+ sciatic nerves I could not observe any specific staining there. However, despite a 
potentially increased background staining, I detected also no specific expression pattern of 
FABP9 in P2-/- sciatic nerves (Fig. 24C). Therefore, it is most likely that the increased 
amount of FABP9 mRNA in P2-/- mice might not be translated into FABP9 protein. 
               
Figure 24 : FABP9 protein expression in P2-/- mice. 
(A) Western Blot analysis showed a strong expression of FABP9 in both P2-/- and P2+/+ testis at P56. 
However, no FABP9 expression was obtained neither in P2-/- sciatic nerves nor in P2+/+ sciatic nerves 
at P10. (B) FABP9 immunostainings revealed the expected expression in cross sections of adult P2+/+ 
and P2-/- testis. Interestingly, the staining intensity in P2-/- testis was much higher. (C) Sciatic nerve 
cross sections of P10-old mice demonstrated a strong P2 expression in P2+/+ mice but not in P2-/- 
mice. However, no specifc stainings were obtained for FABP9 on P2-/- sections similar to P2+/+ 
sections. n=2 
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3.2.5 In vivo analysis of P2-MBP interaction 
 MBP is a small, basic, cytoplasmic myelin protein like P2. It colocalizes with P2 in the 
myelin sheath of peripheral nerves and recent biochemical data suggest that P2 and MBP 
may work together in the formation and maintenance of compact myelin (104). Mice with an 
autosomal recessive mutation for MBP, the Shiverer mice (here: P2+/+/Shi-/-), possess strong 
myelin defects in the CNS but not in the PNS (105, 106). Due to their similarity it is 
suggested that P2 might overtake the function of MBP in the PNS but not in the CNS (107, 
108). To evaluate a possible interaction between P2 and MBP in vivo, I generated double KO 
mice for P2 and MBP (P2-/-/Shi-/-).  
 Similar to P2+/+/Shi-/- mice, the P2-/-/Shi-/- mice developed a severe tremor phenotype by 2 
weeks of age demonstrating the persistent presence of CNS defects. Furthermore, both 
genotypes showed a very severe hindlimb clasping phenotype in adult mice (P56) indicating 
defects in the PNS as well. The body weight and blood glucose levels were equal in mice of 
all genotypes at P56 (Fig. 25A and B) and mice were fertile, producing pubs according to 
expected Mendelian frequency. On the electrophysiological level, both P2+/+/Shi-/- and P2-/-
/Shi-/- mutant mice had a significant lower MNCV at P56 suggesting myelin defects (Fig. 
25C). In addition, P2+/+/Shi-/- had a significant increase in the CMAP amplitude and area while 
this increase was not significant anymore for P2-/-/Shi-/- mice (Table 12).  
 
 
Figure 25 : Characterization of P2+/+/Shi-/- and P2-/-/Shi-/- mice versus P2+/+/Shi+/+ mice at P56. 
While (A) the body weight and (B) the blood glucose level were identical for all three genotypes, (C) 
the MNCV was significantly lower in P2+/+/Shi-/- and P2-/-/Shi-/- mice as compared to P2+/+/Shi+/+ mice. 
n=5. * p-value < 0,05. 
 
 
 
 
 
 
 
  
 
 
 
 
MNCV (m/s) Latency (ms) Duration (ms) Amplitude (mV) Area (mV/ms)
P2+/+/Shi+/+ 39,75 (+/- 5,24) 1,26 (+/- 0,23) 0,96 (+/- 0,09) 1,56 (+/- 1,36) 0,78 (+/- 0,43)
P2+/+/Shi-/- 25,5 (+/- 2,8) 1,15 (+/- 0,11) 0,93 (+/- 0,06) 3,63 (+/- 0,91) 1,55 (+/- 0,38)
p-value 0,0002 0,4209 0,5401 0,0164 0,0178
P2-/-/Shi-/- 28,79 (+/- 3,12) 1,35 (+/- 0,18) 0,97 (+/- 0,22) 3,00 (+/- 1,43) 1,22 (+/- 0,53)
p-value 0,0162 0,5494 0,974 0,1754 0,2612
Table 12 : Properties of the CMAP curve of P2+/+/Shi-/- and P2-/-/Shi-/- mice as compared 
to P2+/+/Shi+/+ mice at P56. 
Besides a significant reduction in MNCV, the CMAP amplitude as well as the CMAP area was 
increased in P2+/+/Shi-/- mice (significantly) and in P2-/-/Shi-/- mice (not significantly) as 
compared to P2+/+/Shi+/+ mice at P56. However, the CMAP latency and duration was not 
different. n=5. p-values are for both mutants as compared to P2+/+/Shi+/+ mice. 
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 Semithin cross sections at P10 and P56 should give information about early and/or late 
alterations of the sciatic nerve morphology (Fig. 26A and B). As previously described (106) 
no major structural defects in PNS myelination could be observed in P2+/+/Shi-/- mice as 
compared to P2+/+/Shi+/+ mice at P10 and P56. Interestingly, deletion of both P2 and MBP in 
P2-/-/Shi-/- mice had as well no significant effects on PNS myelin structure. To evaluate the 
nodal structure I stained teased fibers generated from sciatic nerves of P2+/+/Shi-/-, P2-/-/Shi-/- 
and P2+/+/Shi+/+ mice with Nile Red, a fluorescent stain labeling the lipid-rich myelin (Fig. 
26C). This technique showed a normal formation of the node of Ranvier for both P2+/+/Shi-/- 
and P2-/-/Shi-/- mice as compared to P2+/+/Shi+/+ mice at P56. However, as reported previously 
(30), P2+/+/Shi-/- mice had a strong increase in the number of SLI, a phenotype which was 
less pronounced in P2-/-/Shi-/- mice. 
 A possible cause for the reduced MNCV and increased CMAP amplitude and area in 
P2+/+/Shi-/- and P2-/-/Shi-/- mice may be alterations in ion conductance. Therefore, I compared 
the distribution of Nav- and Kv1-channels in teased fibers of P2+/+/Shi-/- and P2-/-/Shi-/- mice 
with P2+/+/Shi+/+ mice at P56. In all three genotypes Nav-channels were correctly accumulated 
at the node of Ranvier and Kv1-channels at the juxtaparanodes excluding a mislocalization of 
these ion channels along myelinated fibers (Fig. 26D).  
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Figure 26 : Preserved sciatic nerve myelination of P2+/+/Shi-/- and P2-/-/Shi-/- mice at P10 and P56. 
Semithin cross sections of the sciatic nerve (A) at P10 and (B) at P56 of all three genotypes showed 
no differences in the myelination of nerve fibers. (C) Segmental demyelination was excluded by Nile 
Red staining of adult sciatic nerve teased fibers. However, a higher number of SLI in P2+/+/Shi-/- was 
observed which was less severe in P2-/-/Shi-/- mice as compared with P2+/+/Shi+/+ mice. (D) Co-
immunostainings of Nav and Kv1.2 on teased fibers of P56-old mice showed for both P2+/+/Shi-/- and 
P2-/-/Shi-/- mice no defects in the accumulation of ion channels as compared to P2+/+/Shi+/+ mice. 
Again, an increased presence of SLI was observed in P2+/+/Shi-/-. n=3, except ion channel stainings 
n=2. 
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4.  Discussion 
 
4.1 Altered distribution of juxtaparanodal Kv1-channels mediates peripheral 
nerve hyperexcitability in type 2 diabetes mellitus 
 
 In this work, I showed that db/db mice, a mouse model for T2DM, developed a PNH 
phenotype in addition to reduced NCV similar to the one observed in diabetic patients (40, 
61, 62, 89, 90, 109). This phenotype was caused by an altered distribution of juxtaparanodal 
Kv1.2 channels and can be attenuated by flupirtine, suggesting it as a potential drug for PNH 
in T2DM. 
  
4.1.1 db/db mice as a model for type 2 diabetes mellitus and diabetic peripheral 
neuropathy 
 In the last years, the db/db mouse strain became a well established animal model of 
T2DM (69, 70, 110-114). We confirmed previous studies showing altered physiology and 
development of peripheral neuropathy in db/db mice (55, 70, 112) and determined the onset 
of T2DM in db/db mice at 6 weeks of age, immediately followed by DPN at 7 weeks of age. 
At 23 weeks of age, when I analyzed them, the mice were severly diabetic. Moreover, at this 
age β-cell degeneration started in db/db mice, which results in insulin defiency. Therefore, 
db/db mice switch to a more T1DM-like phenotype around the age of 23 weeks (115). Similar 
to previous observations (55), there were no structural changes affecting sciatic nerve 
myelination even after 16 weeks of hyperglycemia that could explain its pronounced 
reduction in MNCV and SNCV. The slight shift in the axonal distribution from small to 
medium size fibers correlated with the loss of IENF and might explain the small fiber 
neuropathy. The reduction of the paranodal adhesion molecule Caspr is not leading to a loss 
of paranodal junctions and might have therefore only minor structural consequences 
confirming a previous freeze-fracture study which found little evidence for axo-glial 
dysjunctions in the paranodal regions of some fibers in 24 weeks old db/db animals (116).  
 
4.1.2 Physiological and mechanistic implication of Kv1-channels in PNH 
 Importantly, we observed for the first time that db/db nerves were more excitable than 
control nerves thus validating it as a model to characterize this part of the DPN phenotype. 
Similar to the situation in diabetic patients where PNH is thought to be responsible for the 
positive symptoms of DPN (40, 61, 62), it could explain allodynia in db/db mice (117). We 
asked if the PNH phenotype in db/db animals led to a prolonged RP and might be causative 
for the reduced NCV. However, we could not observe any alterations in db/db RP as 
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compared to WT mice and therefore conclude that PNH and reduced NCV are two 
independent phenotypes.  
 Clinical studies of immune (Isaac’s syndrome) or genetic (episodic ataxia type 1) 
diseases, caused by alterations in Kv1-channel functions, have demonstrated that the 
pathophysiological consequences on the nerve functions include PNH or myokymia (35, 36, 
38). By pharmacological blocking of the relevant Kv-channels present in the PNS, we clearly 
demonstrated that a reduced activity of Kv1-channels was involved in the PNH phenotype of 
db/db mice. However, inhibition of Kv1-channels of isolated WT nerves did not reproduce the 
hyperexcitability to the same degree as observed in db/db nerves, suggesting the existence 
of other mechanisms involved in db/db nerve hyperexcitability. We excluded slow KCNQ Kv7-
channels (Kv7.2 and Kv7.3) (14, 97) and Nav-channels (54, 56) as candidates indicating that 
this difference may rather reflect variation in accessibility and/or kinetics of action of drugs 
used to block Kv1-channels in either control or db/db animals. The preserved function of Nav-
channels was corroborated by immunostainings on teased fibers of db/db and WT mice at 5 
and 23 weeks of age. However, a pan-Nav antibody was used and thus the immunostaining 
gives no information about the identity of the α-subunit isoform of the nodal Nav-channels in 
db/db versus WT mice. 
 The functional loss of Kv1-channels was in line with an altered distribution of 
juxtaparanodal Kv1.2-channels, in both db/db mice and T2DM patients. These data are in line 
with and extend a previous observation that paranodal/juxtaparanodal potassium binding 
sites (which may represent Kv-subunits) are reduced in nerves from diabetic patients (118) 
and are to our knowledge the first direct demonstration of such an alteration in axonal ion 
channels in diabetic patients. qPCR and western blot analysis excluded a reduced 
expression level of Kv1.2 in db/db mice as being responsible for the lower expression of 
Kv1.2 at the juxtaparanodal regions. Furthermore, myelin defects which could impair ion 
channel localization (99, 101) were also excluded in db/db animals and T2DM patients.  
 Matured and assembled Kv1-channels are transported to their target site at the axolemma 
(119). My preliminary results of Co-IP experiments against Kvβ2 showed a reduced 
attachment of mature Kv1.2 and an increased amount of immature Kv1.2 in db/db mice as 
compared to WT mice. In WT mice the expression of the immature isoform of Kv1.2 is 
enriched in soma-rich DRGs and specifically mature Kv1.2 is transported to the axon (119). 
However, I detected in both western blot and Co-IP analysis an expression of immature 
Kv1.2 even in WT endoneurial extracts. Therefore, I cannot exclude that some of the 
Schwann cell Kv1.2 expression (120) is reflected in my protein analysis of sciatic nerve 
endoneurium and might influence the interpretation of these results, especially concerning 
immature Kv1.2. Furthermore, in the co-immunoprecipitated samples there was no actin (or 
other proteins) present in order to normalize the immunoblots. Kv1-channels are transported 
along axonal microtubuli within post-Golgi carrier vesicles associated with KIF3 and its 
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adaptor protein EB1 (121). Therefore, α/β-tubulin cannot be used as normalizer and thus the 
reduced amount of α/β-tubulin to Kvβ2 demonstrates rather a reduced attachment in db/db 
mice as compared to WT mice than a lower amount of loaded protein. Unpublished data of 
Jeffrey D. Milbrandt communicated at the PNS meeting in 2009 showed a similar failure in 
the localization of Kv1.2 in conditional KO mice of the deacetalyse Sirt2. As previously 
reported, the recruitment of the molecular motor proteins and its adaptor proteins is regulated 
by microtubule acetylation (122). I compared the acetylation status of Sirt2 in db/db and WT 
sciatic nerve endoneurium at 23 weeks of age. Interestingly, my preliminary data showed a 
reduced activity of Sirt2 in db/db mice suggesting potential defects in microtubule dynamics. 
However, further experiments are necessary to prove an involvement of Sirt2 in the 
pathophysiology of T2DM. 
 The reduced amount of integrated Kv1.2 into the membrane in db/db mice as observed in 
my cellular fractionation experiments correlated with the altered Kv1.2 distribution at 
juxtaparanodal regions on teased fibers. However, it was not accompanied by an increased 
expression of Kv1.2 in the cytoplasm of db/db mice maybe because the Kv1.2-subunits are 
still included within transport vesicles. Moreover, it is possible that the different buffer 
composition of western blot, Co-IP and cellular fractionation experiments might have 
influenced these results as even Kv1.2 expression in the total lysate of db/db mice in the 
cellular fractionation experiments was reduced.  
 I conclude, that Kv1.2 is normally expressed in db/db mice but it is clustering to the 
juxtaparanodal regions, which is mediated by the adhesion molecules TAG-1 and Caspr2 
(19), is impaired. As opposed to most ion channel subunits which possess intrinsic targeting 
motifs, both transport and TAG1-mediated clustering of Kv1.2 is mainly dependent on its 
phosphoralytion status (123) which may be affected under diabetic condition. Moreover, 
Kv1.2 subunits are not retained in the cell bodies of (at least) sensory neurons and they 
reach the axoplasm. However, I suggest that most Kv1.2 subunits do not reach their final 
juxtaparanodal regions due to a lower transportation rate or a random release of the 
transport vesicles from the microtubules and/or from the attached KIF3/EB1/Kvβ2-complex 
away from any juxtaparanodal regions being clustered there (Fig. 27). This assumption is 
based on preliminary data and must be further explored. 
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Figure 27 : Putative molecular mechanism underlying altered juxtaparanodal Kv1.2 expression 
in db/db mice. 
In WT mice Kv1-channels, consisting of 4 α- and 4 β-subunits are integrated into transport vesicles. 
Within these vesicles they are transported to their juxtaparanodal targets along microtubuli which is 
triggered by the motor protein complex of KIF3/EB1. My preliminary results revealed a potential 
reduced interaction of Kvβ2 with Kv1.2 and Tubulin and/or impaired maturation (indicated in red) of 
Kv1.2 in db/db mice at 23 weeks of age. Consequently, less Kv1.2 might reach the juxtaparanodal 
regions of the axolemma. 
 
4.1.3 Therapeutical applications 
 How does hyperglycemia damage peripheral nerves? This is still an unanswered question 
which makes it difficult to develop efficient therapies for DPN. Therefore, the best therapy is 
still to achieve normal blood glucose levels in diabetic patients e.g. by insulin therapies. Our 
data indicate at least two different approaches how to improve DPN condition (particularly 
PNH) for which there are no effective therapies. First, one may try to enhance the targeting 
of Kv1.2 to its juxtaparanodal location thus improving the hypersensitivity phenotype. 
Alternatively, our expression and pharmacology data generated in db/db mice showed that 
there are multiple ion channel-types (including Nav1.6, Kv1.1, Kv7.2 and Kv7.3) that are well 
preserved in the diabetic peripheral nerve. Both the inhibition of Nav-channels and the 
activation of preserved Kv-channels might alleviate the PNH phenotype. We validated the 
clinical potential of the second approach by suppressing PNH in db/db nerves with the Kv7-
activator flupirtine. Interestingly, flupirtine, which is an analgesic, has already been shown to 
suppress PNH resulting from exposure of rat and human peripheral nerves to oxaliplatin (98). 
 Overall, my study focused on T2DM, the major form of DM. However, it would be of 
interest if these results and the therapeutical suggestions might be adapted to other 
diseases. This might compass diseases with described Kv1-mediated PNH as shown for 
amyotrophic lateral sclerosis (37) or other forms of DM, e.g. T1DM. While some groups claim 
more severe nodal and paranodal defects in T1DM patients and rats than in T2DM (58, 124, 
125), others described no alterations in the expression of any nodal, paranodal or 
juxtaparanodal marker (126). Therefore, further studies are required to clarify the 
pathological differences (or similarities) between T1DM and T2DM. 
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4.2 Generation of a knockout mouse model to study the role of peripheral 
myelin protein P2  
 
 P2 is a small lipid-binding protein, localized at the cytoplasmic side of some myelin 
sheaths in the PNS (79, 80). I confirmed and extended the unique expression profile of P2. 
The most striking feature of P2 expression was its presence in only some myelin sheaths 
which raises up challenging questions concerning P2: what is the difference between P2-
postive and P2-negative Schwann cells? What is the functional role of P2? To get some 
insight into the function of P2 I generated a P2-/- mouse model. Surprisingly, the P2-/- mice 
showed no major defects in myelination of the PNS as compared with P2+/+ mice. However, 
the results of gene profiling indicated a potential role of P2, which is a member of the FABP 
family, in the glial lipid metabolism. 
 
4.2.1 P2 expression 
 The developmental expression profile of P2 correlated very well with that of other major 
peripheral myelin proteins like MBP and MPZ. However, the P2 expression is most likely 
differentially regulated as MBP or MPZ leading to a partial and more longstanding expression 
in peripheral myelin. By immunostainings of P2 on dorsal and ventral roots I excluded the 
nerve fiber function as possible regulator, as suggested earlier (80). While in sciatic nerve 
cross sections predominantly large nerve fibers were P2-positive, immunostainings on 
teased fibers further excluded the fiber size as the only factor regulating P2 expression. 
Interestingly, FABP expression is known to be proportional to the rate of lipid metabolism 
within the cell (71). As Schwann cells associated with large fibers start first to myelinate and 
show as well a higher lipid (and protein) demand this might explain the fact that 
predominantly large fibers were labeled by P2 but not the differences along the same fiber. 
The expression rate in Schwann cells associated with small fibers might be too small to be 
detected by immunostaining approaches. Possibly, P2 is also involved in myelin 
maintenance and/or myelin repair explaining its expression in only some myelin sheaths. 
Interestingly, in P2+/- mice the majority of Schwann cells reacted to X-Gal although the LacZ 
gene was under the control of the P2 promoter. Thus, this supports my hypothesis that all 
Schwann cells are theoretically able to produce P2.  
 While MPZ and MBP, involved in myelin compaction, are specifically located in the myelin 
sheaths, P2 showed a strong expression in the Schwann cell cytoplasm as well (79). As 
FABPs are known to be cytoplasmic, it might correlate with its potential role in FA binding 
and transport from the cell cytoplasm into the myelin sheath. Previously described as a 
peripheral membrane protein (79), P2 might maintain or store the lipids afterwards within the 
lipid sheath. This can be achieved either indirectly by interactions to another peripheral 
myelin protein or directly by interactions to lipid components via its potential myristoylation 
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domain (77) or by unspecific electrostatic interactions of the positively charged P2 protein 
with the negatively charged myelin membrane. 
 In situations of demyelination P2 is present in some of the thin myelin sheaths which are 
labeled by MBP as in healthy nerves. The more pronounced cytoplasmic expression of P2 in 
Lpin1-/- mice might be correlated to the dedifferentiation of Schwann cells to more immature 
Schwann cells. However, in demyelinating nerves of Lpin1-/- mice I noticed myelin sheaths 
that were only postive for P2 but not for MBP. I never oberved such myelin sheaths in P2+/+ 
mice neither at P56 nor at P10 highlighting a potential role of P2 in myelin maintenance 
and/or repair.  
 
4.2.2 Peripheral nerve function in P2-/- mice 
 Unexpectedly, the P2-/- mice did not show any gross morphological alterations in PNS 
myelination. However, this stays in correlation with other KO mouse models of the FABP 
family. In none of them gross alterations have been observed possibly due to compensatory 
mechanisms by other FABPs expressed in the same tissue (71). Despite normal myelinated 
peripheral nerves in P2-/- mice as compared to P2+/+ mice, I observed a mild but significant 
downregulation of the MNCV in P56-old P2-/- mice. While the reduced MNCV did not lead to 
a prolonged CMAP latency or duration it was accompanied by a significant increase in CMAP 
area and amplitude. The combination of reduced MNCV and increased CMAP amplitude and 
area is described for reinnervation of a muscle after nerve injury accompanied by de- and 
remyelination (127). However, this was not the case in the P2-/- mice. Moreover, nodal Nav- 
and juxtaparanodal Kv1-channels were normally expressed and could not contribute to the 
observed phenotype. Therefore, it has to be analyzed if more subtle alterations in myelin 
structure and/or myelin composition might impair the isolating property of the myelin sheath. 
 
4.2.3 Lipid homeostasis-related role of P2 in Schwann cells 
Through my transcriptomic analysis of sciatic nerves of P10-old P2-/- versus P2+/+ mice, I 
observed significant alterations in the mRNA expression level of two other FABP family 
members. FABP5 was significantly downregulated while FABP9 was significantly and highly 
upregulated, indicating that the loss of P2 might have major effects on the glial lipid 
metabolism. Such an upregulation of FABP9 is suggestive for a compensatory effect as 
observed in adipocytes from FABP4-/- mice by FABP5. But in this situation FABP5 is already 
present in small amounts in normal adipocytes whereas FABP9 is not expressed in         
P2+/+ sciatic nerves. 
Interestingly, qPCR analysis of P56-old P2-/- versus P2+/+ mice revealed a differential 
expression of FABP5 and FABP9 not only in sciatic nerve endoneurium but also in other 
tissues tested. This is unexpected as P2 is specifically expressed in sciatic nerve 
endoneurium in P2+/+ mice and in no other tissues. Furthermore, I could not detect any 
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FABP9 protein expression in P2-/- sciatic nerves at P10 by both western blot analysis and 
immunostainings suggesting that FABP9 mRNA is not translated into protein. 
P2 is located on mouse chromosome 3 in a gene cluster together with FABP4/5/9 and 
12 which is conserved in other mammalian species, e.g. human and rat. Such conserved 
chromosomal regions are often maintained together as they are regulated by common non-
coding cis- or trans-acting elements (128, 129). Indeed, in humans there is an annotated 
anti-sense non-coding RNA (ncRNA) that maps to the 3' end of P2 and overlaps FABP9 (and 
FABP4) (Fig. 28A, B). It is most likely that the same ncRNA is also present in mice and that 
the loss of antisense mediated repression induced the observed upregulation of FABP9 in 
P2-/- mice. Analysis of the P2 expression in FABP9-/- mice might demonstrate if P2 is also 
regulated by this ncRNA. In addition, on the mouse track of embryonic stem cells appears an 
epigenetic mark (methylation) associated with the cis regulatory sequences in the last exon 
of P2 (Fig. 28C). This might play a role as an active regulatory enhancer. The loss of it may 
be responsible for the downregulation of FABP5 and/or of the anti-sense ncRNA. Therefore, 
the functional relevance of the altered mRNA expression of FABP5 and FABP9 is still 
elusive. 
 
Figure 28 : The epigenetic and transcriptional landscape of the P2 locus.  
(UCSC Gene annotations) 
(A) Human genomic region containing the coding transcripts (blue) of P2 (= Pmp2, FABP8), FABP9, 
FABP4 and FABP12. Non-coding transcripts are represented in green. Importantly, a long non-coding 
RNA was annotated to the 3‘ end of P2 which overlaps FABP9 and FABP4 (red arrow). It consists of 
three exons (small red numbers) which are spliced as for coding transcripts. At the bottom the green 
bar graphs show highly conserved regions in mammals. (B) Enlarged view of human P2 locus. The 
first two exons of the long non-coding RNA are just after the coding P2 transcript and correlates with a 
highly conserved regions in mammals. The second annotated P2 transcript (lower one) encodes most 
likely a intragenic enhancer and has no protein-coding potential. (C) In mouse embryonic stem cells 
(ES) the last exon of the P2 gene is epigenetically marked by methylation (p300 and H3K4me1 marks) 
(red arrow) which might act as a putative enhancer. 
 
The physiological characterization of P2-/- mice revealed a significant increase of the 
plasma insulin levels at P56 suggestive for insulin resistance. Alterations in the insulin 
metabolism, induced by increased levels of FFA, is commonly described for other FABP KO 
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mouse models (71). FFA-induced insulin resistance is often associated with an altered 
production of adipocyte-related genes, like Resistin and Adiponectin, prior to alterations in 
the immune response (130). While I could not observe any alterations in FFA levels in 
plasma samples of P2-/- mice as compared to P2+/+ mice at P10 and P56, my microarray data 
revealed differential expression of relevant adipocyte-related genes in P2-/- mice already at 
P10 which might contribute to the development of insulin resistance at P56. 
 
To clarify the potential role of P2 in the lipid homeostasis of the neuronal system I am 
currently characterizing the FA and lipid composition of sciatic nerve myelin in P2-/- mice as 
compared to P2+/+ mice at P10. Moreover, I will make use of already established DRG 
explants of P2-/- and P2+/+ mice to evaluate the ability of FA uptake in vitro. 
Apart from that, P2 is known to be a target of autoimmune reactions in patients with GBS 
(48). In collaboration with Dr. Mark Stettner at the Department of Neurology at the Heinrich-
Heine-University in Düsseldorf (Germany) we might have access to plasma samples of GBS 
patients. To validate the relevance of the P2 protein in GBS we plan to inject P2-/- and P2+/+ 
mice with the human plasma samples. 
 
4.2.4 P2 and MBP are two independent myelin genes 
To evaluate the suggested interplay between P2 and MBP in vivo I generated P2-/-/Shi-/- 
mice (104). While P2+/+/Shi-/- mice possess major myelin defects in the CNS, resulting in a 
severe tremor phenotype, the PNS remains mainly unaffected (105, 106, 131). However, a 
dramatic increase in the number of SLI in the PNS of P2+/+/Shi-/- mice has been reported 
previously (30). After my knowledge, I have for the first time measured the MNCV of the 
sciatic nerve in P2+/+/Shi-/- mice and observed a significant downregulation of the speed as 
compared to P2+/+/Shi+/+ mice at P56. This might correlate at least to some extent to the 
increased number of SLI. Such an increase in the number of SLI was also described for 
cerebroside sulfotransferase-deficient mice but these mice had a normal MBP expression. 
The effects on nerve function was not described (132). Despite the loss of P2, P2-/-/Shi-/- mice 
showed no further impairment of the MNCV compared to  P2+/+/Shi-/- mice. I rather observed 
a slight tendency to a faster MNCV in P2-/-/Shi-/- mice (Table 12). Interestingly, the increase 
of SLI in teased sciatic nerves was much less pronounced in P2-/-/Shi-/- as compared to 
P2+/+/Shi-/- mice. In addition to the reduced MNCV I observed a significant increase in CMAP 
amplitude and area in P2+/+/Shi-/- mice at P56. As for the number of SLI, this phenotype was 
improved in P2-/-/Shi-/- mice as compared to P2+/+/Shi-/- mice even though I measured as well 
an increase in CMAP area and amplitude for P2-/- mice as compared to P2+/+ mice at P56. 
The reason for the increased CMAP area and amplitude remains elusive. In chapter 4.2.2 I 
suggested that more subtle alterations of the myelin sheath or the myelin composition might 
provoke such alterations in the electrophysiology of the nerve. Interestingly, major alterations 
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in the lipid composition of sciatic nerve myelin of P2+/+/Shi-/- as compared to P2+/+/Shi+/+ mice 
have been reported accompanied by enhanced hypotonic swellings in the extracellular space 
(133). Consequently, the higher amount of negatively charged lipids changed the 
electrostatic properties of the myelin sheath and might impair its isolating function and/or the 
ion current. Thus, the results of the lipid profiling of P2-/- sciatic nerve myelin will help to 
understand the consequences of the additional loss of P2 in P2-/-/Shi-/- mice.   
 A potential improvement of the phenotypes in P2+/+/Shi-/- mice by the loss of P2 was 
unexpected. Interestingly, a similar situation was described for double KO mice for MBP and 
proteolipid protein (PLP) in the CNS (134). These double KO mice for MBP and PLP had not 
only a longer lifespan and less pronounced tremors, they showed also an improvement in 
myelination of the optic nerve as compared to P2+/+/Shi-/- mice.  
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5.  Collaborative projects 
 
5.1 Global transcriptional programs in peripheral nerve endoneurium and 
DRG are resistant to the onset of type 1 diabetic neuropathy in Ins2Akita/+ 
mice 
 In the research field of DM a lot of effort is put into the understanding of the morphological 
and electrophysiological alterations in diabetic patients or appropriate animal models. 
However, the potential molecular changes in DPN still remain elusive. We decided to use a 
genetic mouse model of T1DM, the Akita mice (Ins2Akita/+) (Table 4), to compare the 
transcriptional profiles of presymptomatic and symptomatic animals. To do so, we 
characterized the onset and progression of T1DM and DPN in these mice. I had the 
opportunity to contribute to this publication by performing the morphometric analysis of 
Ins2Akita/+ mice as compared to Ins2+/+ mice including g-ratio and axonal distribution analysis 
on toluidin-blue stained semithin cross sections. Moreover, I determined the IENF density by 
PGP9.5 immunostainings on hindpaw cryostat sections of Ins2Akita/+ and Ins2+/+ mice.  
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5.2 Mouse model of Charcot-Marie-Tooth disease type 4C 
 In 2003, Sh3tc2 (= KIAA1985) was identified as the causative gene for CMT4C, a 
recessive demyelinating form of CMT diseases (135). However, the role of Sh3tc2 protein 
was completely unknown. Sh3tc2 possess two SH3-domains, multiple TRP domains and a 
myristilation domain which might connect it to the plasma membrane. Mutations appearing in 
human patients are randomly distributed within the protein, including both missense and 
nonsense mutations. The disease is characterized by an early onset, progressive muscle 
weakness, reduced MNCV and is often associated with scoliosis. In order to understand the 
pathophysiological mechanism of CMT4C we analyzed the function of Sh3tc2 in vitro and in 
vivo in Sh3tc2∆Ex1/∆Ex1 mice that we generated. 
 
I contributed to the publication below with the following experiments: 
-   participitation in mouse dissections and tissue collections 
- accomplishment of the microarray analysis comparing the gene expression of 
Sh3tc2∆Ex1/∆Ex1 and Sh3tc2+/+ sciatic nerve endoneurium at P28 
- characterization of the nodal phenotype in Sh3tc2∆Ex1/∆Ex1 mice by co-immunostainings on 
teased fibers 
- contribution to qPCR and Western blot analysis of various myelin markers in Sh3tc2∆Ex1/∆Ex1 
sciatic nerves as compared to Sh3tc2+/+ mice 
- Sh3tc2 antibody testing to detect its endogenous expression  
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5.2.1 SH3TC2/KIAA1985 protein is required for proper myelination and the integrity of 
the node of Ranvier in the peripheral nervous system 
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5.2.2 SH3TC2, a protein mutant in Charcot–Marie–Tooth neuropathy, links peripheral  
 nerve myelination to endosomal recycling 
In our recent paper (45) (chapter 5.2.1.), we have shown that Sh3tc2∆Ex1/∆Ex1 mice developed 
a peripheral neuropathy similar to the one observed in CMT4C patients. However, it is still an 
open question how the loss of Sh3tc2 can affect PNS myelination. Interestingly, Sh3tc2 
protein contains multiple protein-protein interaction domains but no binding partner has been 
identified so far. Here, we show a clear interaction between Sh3tc2 with Rab11 which is 
disrupted by mutations in the Sh3tc2 gene. This finding links peripheral neuropathy to the 
mechanism of endocytic recycling.    
I performed the microarray analysis and contributed to the Western Blot analysis of Rab11 
on sciatic nerves of P5-old Sh3tc2∆Ex1/∆Ex1 versus Sh3tc2+/+ mice. 
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5.3 Characterization of a mouse model of Charcot-Marie-Tooth disease type 
4A and 2K 
(ongoing collaboration with Paula Juárez Gómez in the lab of Francesc Palau at the “Instituto 
de Biomedicina de Valencia” in Spain) 
 Mutations in genes encoding for mitochondrial proteins were previously linked to CMT 
disease (43). One of these genes is the ganglioside-induced-differentiation-associated 
protein 1 (GDAP1), which might be a member of the glutathione-S-transferase enzyme family 
(136, 137). GDAP1 is located at the outer membrane of the mitochondria and is most likely 
involved in the fission of these organelles. Previous studies demonstrated a strong 
expression of GDAP1 in both sensory and motor neurons of the PNS and in numerous 
neurons of the CNS (136, 138). While some studies report a glial expression of GDAP1 as 
well, others did not find any expression of GDAP1 in Schwann cells (138, 139).  
 More than 20 mutations in the GDAP1 gene are known to cause either a demyelinating 
(CMT4A) (140, 141), an axonal (CMT2K) (136, 142) or an intermediate (CMTRIA) (143, 144) 
form of CMT diseases. CMT4A shows autosomal recessive inheritance, whereas CMT2K 
can be both recessively and dominantly inherited. It has been difficult to demonstrate if 
GDAP1 mutations lead primarily to myelin or axonal defects in the PNS. Various missense 
constructs of GDAP1 tested in vitro led to contradictory results, mostly to mitochondrial 
fragmentation but also to mitochondrial aggregation (138). Therefore, different molecular 
mechanisms might cause the diverse phenotypes. In order to understand the role of GDAP1 
in mitochondrial biology and in disease situation, the group of F. Palau in Valencia (Spain) 
has recently established a KO mouse model for GDAP1 (GDAP1-/-). In GDAP1-/- mice the first 
exon was conditionally deleted using the Cre/LoxP-system. I participated in the 
electrophysiological and morphological characterization of these mice as follows: 
 Rotarod experiments performed by Paula J. Goméz in Valencia (Spain) revealed a 
significantly reduced latency to fall for GDAP1-/- mice as compared with GDAP1+/+ mice at 3 
and 5 months of age. Furthermore, all GDAP1-/- mice and even some GDAP1+/- mice showed 
a typical hindlimb clasping phenotype, indicating a peripheral neuropathy. To further evaluate 
functional defects of GDAP1-/- mice I received 2 and 5 months old male mice from P. Gomez. 
The mice were overall healthy although the GDAP1-/- mice had significantly lower body 
weight at 5 months of age as compared with age-matched control mice (Fig. 29A). A slight 
increase in blood glucose levels was detectable for both genotypes at 2 months of age which 
was decreased at 5 months of age back to normal levels in both GDAP1-/- and GDAP1+/+ 
mice (Fig. 29B). Interestingly, at both ages I obtained a slight reduction of the MNCV for 
GDAP1-/- mice which became significant at 5 months of age probably due to a lower 
variability of the measurements (Fig. 29C, Table 13). Further analysis of the CMAP curve 
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revealed a significant reduction in CMAP latency, area and amplitude in GDAP1-/- mice 
compared to GDAP1+/+ mice at 5 months of age but not at 2 months of age (Table 13).  
 
Figure 29 : Physiological properties of 2 and 5 months old GDAP1-/- mice as compared to 
GDAP1+/+ mice. 
(A) While the body weight was not different at 2 months of age, GDAP1-/- mice had a significantly 
lower body weight at 5 months of age. (B) At 2 months of age both genotypes had slightly increased 
blood glucose levels, while it decreases to normal levels at 5 months of age for both GDAP1-/- and 
GDAP1+/+ mice. (C) Interestingly, young as well as old GDAP1-/- mice had a slight reduction in MNCV 
which became significant at 5 months as compared to GDAP+/+ mice. n=4; * p-value < 0,05; 
 
 
 
 
Table 13 : Shape of the CMAP curve of GDAP1-/- and GDAP1+/+ mice at 2 and 5 months of age. 
(A) At 2 months of age MNCV, CMAP latency, duration, amplitude and area were normal in GDAP1-/- 
mice as compared to GDAP1+/+ mice. (B) At 5 months of age, MNCV and CMAP latency were 
significantly reduced. Furthermore, a significant reduction in CMAP amplitude and area suggested 
axonal loss in GDAP1-/- mice. CMAP duration was not significantly altered in GDAP1-/- versus 
GDAP1+/+ mice. n=4; 
 
 To corroborate our electrophysiological and behavioral observations, I performed semithin 
cross sections of the sciatic nerve of GDAP1-/- and GDAP1+/+ mice at 2 and 5 months of age 
(Fig. 30A, B). Interestingly, I could not observe any gross alterations in both sciatic nerve 
myelination and axonal morphology. Furthermore, counting the number of myelinated fibers 
per sciatic nerve did not reveal any axonal loss in GDAP1-/- as compared to GDAP1+/+ mice 
at both ages (Fig. 30C). 
2m MNCV (m/s) Latency (ms) Duration (ms) Amplitude (mV) Area (mV/ms)
GDAP1+/+ 37,17 (+/- 7,97) 1,22 (+/- 0,02) 1,56 (+/- 0,18) 3,2 (+/- 0,99) 1,54 (+/- 0,4)
GDAP1-/- 34,87 (+/- 7,08) 1,2 (+/- 0,15) 1,38 (+/- 0,4) 2,42 (+/- 0,59) 1,22 (+/- 0,29)
p-value 0,4645 0,951 0,3067 0,1413 0,184
5m MNCV (m/s) Latency (ms) Duration (ms) Amplitude (mV) Area (mV/ms)
GDAP1+/+ 39,69 (+/- 2,66) 1,36 (+/- 0,04) 0,85 (+/- 0,04) 3,6 (+/- 1,76) 1,48 (+/- 0,64)
GDAP1-/- 36,5 (+/- 2,47) 1,18 (+/- 0,05) 0,97 (+/- 0,05) 2,19 (+/- 0,98) 0,95 (+/- 0,38)
p-value 0,0113 0,0024 0,1167 0,0264 0,0346
A 
B 
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Figure 30 : Preserved sciatic nerve morphology of GDAP1-/- mice at 2 and 5 months of age. 
(A) Semithin cross sections  of GDAP1+/+ and GDAP1-/- sciatic nerves at 2 months of age and (B) 5 
months of age revealed no gross defects in the sciatic nerve myelination and axonal morphology. (C) 
Both GDAP1+/+ and GDAP1-/- mice had equal numbers of axons per sciatic nerve at both ages. n=3; 
 
 The clinical characteristics of patients with GDAP1 mutations (CMT4A, CMT2K or 
CMT4RIA) are severe with an early-onset and progressive evolution of muscle weakness in 
feet and hands, atrophy, areflexia and motor-sensory neuropathy (142). However, the newly 
generated KO mouse model for GDAP1 developed normal. As the increased blood glucose 
levels were measured for both genotypes and only at 2 months of age, I conclude that this 
was unrelated to the GDAP1 mutation. Possibly, induced by the change of food or by the 
stress of the transport. Interestingly, GDAP1-/- mice revealed a lower body weight at 5 
months of age than GDAP1+/+ mice. In this regard, it would be of interest to measure 
specifically the weight of muscles in GDAP1-/- mice as compared to GDAP1+/+ as it might 
reflect the severe muscle weakness and atrophy as reported for GDAP1 patients (142). At 2 
months of age I could not observe any significant differences in sciatic nerve function and 
morphology of GDAP1-/- versus GDAP1+/+ mice. Interestingly, at 5 months of age GDAP1-/- 
mice had both a significant reduction in MNCV and CMAP latency indicative for a 
demyelinating phenotype and a significantly reduced CMAP amplitude and area indicative for 
axonal alterations. Such a mixed phenotype correlates with the clinical manifestations of 
GDAP1 patients as previously described (143). However, I could neither observe any signs 
of demyelination nor axonal loss on semithin cross sections of GDAP1-/- as compared to 
GDAP1+/+ mice at 5 months of age. Potentially, structural alterations might be detectable in 
older animals (about 1 year of age) as previously described for a KO mouse model for 
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CMT2A (44). Furthermore it is possible that the electrophysiological alterations are due to 
changes in ion channels or defects at the neuromuscular junctions that were not evaluated. 
Even though I did not observe any demyelination, the electrophysiological deficits may be 
caused by more subtle myelin defects. If the resistance of myelin decreases it will lead to a 
partial loss of the electrical signal. Electron microscopic analysis and immunostainings on 
teased fibers for the various ion channels could clarify this hypothesis. Furthermore, since 
GDAP1 is a mitochondrial protein it might affect the functionality and/or morphology of 
neuronal mitochondria, a hypothesis which should be further explored as well. 
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5.4 Characterization of a knockout mouse model of PLEKHG5 
  Lower motor neuron diseases (LMND) are a group of heterogenous disorders defined by 
progressive paralysis due to motor neuron degeneration and consequent muscle 
denervation. In 2007, the pleckstrin homology domain-containing, family G member 5 
(PLEKHG5) gene was identified to be one of the causative genes for LMND (145). This form 
of LMND is autosomal recessively inherited with an early onset leading to tetraplegia in 
adulthood (146). PLEKHG5 is known to be ubiquitiously expressed with the highest 
expression in the PNS (145). Transfection of mutated PLEKHG5 protein in vitro 
demonstrated a reduced PLEKHG5 stability and reduced activity of the nuclear factor κB 
(NFκB) which is induced by PLEKHG5 as reported previously (145, 147). Interestingly, an 
accumulation of mutated PLEKHG5 protein was specifically observed in a neuronal cell line 
(145). 
 To investigate the role of PLEKHG5 in PNS and LMND pathology we received PLEKHG5 
KO female mice (PLEKHG5-/-) from Jay Baraban (John Hopkins Hospital in Baltimore (USA)). 
I performed physiological and electrophysiological measurements on these mice as 
compared to PLEKHG5+/+ mice at 6 months of age.  PLEKHG5-/- mice developed healthy like 
PLEKHG5+/+ mice without any obvious behavioral or walking deficits at 6 months of age. 
Body weight was normal while blood glucose levels were slightly increased in PLEKHG5-/- 
mice (Fig. 31A, B). Interestingly, overall MNCV recordings on the sciatic nerve revealed a 
mild but significant reduction in PLEKHG5-/- mice as compared to PLEKHG5+/+ mice (Fig. 
31C and table 14). The resulting CMAP curves had a significant slower CMAP latency, 
duration and F-wave latency in mutant animals (Table 14).  
 
Figure 31 : Physiological characterization of PLEKHG5-/- mice at 6 months of age. 
(A) PLEKHG5-/- mice had same body weight as PLEKHG5+/+ mice at 6 months of age. (B) The blood 
glucose levels of PLEKHG5-/- animals were slightly but significantly increased as compared to 
PLEKHG5+/+ mice. (C) Moreover, a slight but significant decrease in MNCV was observed in 
PLEKHG5-/- mice. n of PLEKHG5+/+ = 3; n of PLEKHG5-/- = 5; * p-value < 0,05. 
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Table 14 : Properties of the CMAP curve of 6 months old PLEKHG5-/- and PLEKHG5+/+ mice. 
In addition to the reduced MNCV, CMAP latency, duration and F-wave latency was significantly 
reduced in PLEKHG5-/- mice. CMAP amplitude and area did not change significantly in PLEKHG5-/- 
mice as compared to PLEKHG5+/+ mice. n of PLEKHG5+/+ = 3; n of PLEKHG5-/- = 5; 
 
 
 Patients with mutated PLEKHG5 suffer of severe paralysis from childhood on 
accompanied with either a normal or reduced MNCV (145). While I could not observe any 
major phenotypical alterations of PLEKHG5-/- mice compared to PLEKHG5+/+ mice at 6 
months of age I observed a significant reduction in MNCV. However, only 3 PLEKHG5-/- mice 
contributed to the overall reduction in MNCV whereas 2 other PLEKHG5-/- mice had normal 
values as for PLEKHG5+/+ mice similar to the situation in patients. Together with the 
reduction of CMAP latency, duration and F-wave latency the reduced MNCV is suggestive 
for isolating defects of the myelin sheath around peripheral nerves. Moreover, motor neuron 
loss was observed in patients, most likely due to a downregulation of the anti-apoptotic factor 
NFκB (145). However, I could not observe any alterations in CMAP amplitude and area 
which are suggestive for motor axonal loss. Morphological analysis of the sciatic nerve, 
spinal cord and hind limb muscles will be carried out in our lab and should help to identify 
potential defects in peripheral nerve myelination, motor neuron survival and muscle 
innervation. 
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